ALPHASUITEATLASTM
TLR4 · O00206Homo sapiens
PROTEIN OVERVIEW

TLR4Toll-like receptor 4

O00206Homo sapiensReviewed · UniProt

Transmembrane receptor that functions as a pattern recognition receptor recognizing pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) to induce innate immune responses via downstream signaling pathways.

Sequence839 aa
Source mass95.68 kDa
Recorded PDB entries15
Isoforms listed3

UniProt locations Cell membrane · Early endosome · Cell projection, ruffle

01

Function

Transmembrane receptor that functions as a pattern recognition receptor recognizing pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) to induce innate immune responses via downstream signaling pathways [4, 20, 22, 23, 25, 29, 31, 33, 37, 38, 47, 21]. At the plasma membrane, cooperates with LY96 to mediate the innate immune response to bacterial lipopolysaccharide (LPS) [37]. Also involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni(2+) [31].

Mechanistically, acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response [4, 27, 37, 43, 1]. Alternatively, CD14-mediated TLR4 internalization via endocytosis is associated with the initiation of a MYD88-independent signaling via the TICAM1-TBK1-IRF3 axis leading to type I interferon production [17]. In addition to the secretion of pro-inflammatory cytokines, initiates the activation of NLRP3 inflammasome and formation of a positive feedback loop between autophagy and NF-kappa-B signaling cascade [41].

In complex with TLR6, promotes inflammation in monocytes/macrophages by associating with TLR6 and the receptor CD86 [33]. Upon ligand binding, such as oxLDL or amyloid-beta 42, the TLR4:TLR6 complex is internalized and triggers inflammatory response, leading to NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway [33]. In myeloid dendritic cells, vesicular stomatitis virus glycoprotein G but not LPS promotes the activation of IRF7, leading to type I IFN production in a CD14-dependent manner [18, 33].

Required for the migration-promoting effects of ZG16B/PAUF on pancreatic cancer cells [42]. Acts as an activator of necroptosis, a programmed cell death process, in macrophages (By similarity). In response to LPS, recruits the adapter TRIF/TICAM1, which binds and activates RIPK3 kinase, leading to phosphorylation and activation of MLKL, triggering execution of programmed necrosis via disruption of the plasma membrane (By similarity).

TLR4-mediated necroptosis is independent of TNF-mediated signaling (By similarity)

By similarityExperimental evidence 16 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "Q9QUK6"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "10835634"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "14517278"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15265881"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15809303"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15852007"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "16622205"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17292937"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17478729"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17803912"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20037584"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20711192"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "23880187"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "27022195"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "29038465"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "36945827"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "9237759"
        }
      ],
      "value": "Transmembrane receptor that functions as a pattern recognition receptor recognizing pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) to induce innate immune responses via downstream signaling pathways (PubMed:10835634, PubMed:15809303, PubMed:16622205, PubMed:17292937, PubMed:17478729, PubMed:20037584, PubMed:20711192, PubMed:23880187, PubMed:27022195, PubMed:29038465, PubMed:17803912, PubMed:15852007). At the plasma membrane, cooperates with LY96 to mediate the innate immune response to bacterial lipopolysaccharide (LPS) (PubMed:27022195). Also involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni(2+) (PubMed:20711192). Mechanistically, acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:10835634, PubMed:21393102, PubMed:27022195, PubMed:36945827, PubMed:9237759). Alternatively, CD14-mediated TLR4 internalization via endocytosis is associated with the initiation of a MYD88-independent signaling via the TICAM1-TBK1-IRF3 axis leading to type I interferon production (PubMed:14517278). In addition to the secretion of pro-inflammatory cytokines, initiates the activation of NLRP3 inflammasome and formation of a positive feedback loop between autophagy and NF-kappa-B signaling cascade (PubMed:32894580). In complex with TLR6, promotes inflammation in monocytes/macrophages by associating with TLR6 and the receptor CD86 (PubMed:23880187). Upon ligand binding, such as oxLDL or amyloid-beta 42, the TLR4:TLR6 complex is internalized and triggers inflammatory response, leading to NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway (PubMed:23880187). In myeloid dendritic cells, vesicular stomatitis virus glycoprotein G but not LPS promotes the activation of IRF7, leading to type I IFN production in a CD14-dependent manner (PubMed:15265881, PubMed:23880187). Required for the migration-promoting effects of ZG16B/PAUF on pancreatic cancer cells (PubMed:36232715). Acts as an activator of necroptosis, a programmed cell death process, in macrophages (By similarity). In response to LPS, recruits the adapter TRIF/TICAM1, which binds and activates RIPK3 kinase, leading to phosphorylation and activation of MLKL, triggering execution of programmed necrosis via disruption of the plasma membrane (By similarity). TLR4-mediated necroptosis is independent of TNF-mediated signaling (By similarity)"
    }
  ],
  "commentType": "FUNCTION"
}

Additional functional context

His-456 and His-458 are found in TLR4 of human and several other primate species and may be responsible for inflammatory responses triggered by nickel (Ni(2+)). Ni(2+) may cross-link the two receptor monomers through specific histidines, triggering the formation of a dimer that structurally resembles that induced by LPS. This process may be the basis for the development of contact allergy to Ni(2+).

A mouse model of contact allergy to Ni(2+) in which TLR4-deficient mice expresses human TLR4 has been proposed

Curator inference 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000305",
          "source": "PubMed",
          "id": "20711192"
        }
      ],
      "value": "His-456 and His-458 are found in TLR4 of human and several other primate species and may be responsible for inflammatory responses triggered by nickel (Ni(2+)). Ni(2+) may cross-link the two receptor monomers through specific histidines, triggering the formation of a dimer that structurally resembles that induced by LPS. This process may be the basis for the development of contact allergy to Ni(2+). A mouse model of contact allergy to Ni(2+) in which TLR4-deficient mice expresses human TLR4 has been proposed"
    }
  ],
  "commentType": "MISCELLANEOUS"
}

GO functions & biological processes

lipopolysaccharide-mediated signaling pathwayNOT|acts upstream of or withinUniProtKB:O00206
GO
GO:0031663 · evidence & context
  • ECO:0000314 PMID:10880523 ↗ IDA · MGI · 20130227
    qualifier: NOT|acts_upstream_of_or_within
positive regulation of canonical NF-kappaB signal transductionacts upstream ofUniProtKB:O00206
GO
GO:0043123 · evidence & context
lipopolysaccharide-mediated signaling pathwayacts upstream of or withinUniProtKB:O00206
GO
GO:0031663 · evidence & context
  • ECO:0000316 PMID:10880523 ↗ IGI · MGI · 20130227
    qualifier: acts_upstream_of_or_within
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O95711"}]}]
  • ECO:0000316 PMID:10880523 ↗ IGI · MGI · 20130227
    qualifier: acts_upstream_of_or_within
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y6Y9"}]}]
response to lipopolysaccharideacts upstream of or withinUniProtKB:O00206
GO
GO:0032496 · evidence & context
  • ECO:0000314 PMID:12594207 ↗ IDA · MGI · 20090913
    qualifier: acts_upstream_of_or_within
positive regulation of transcription by RNA polymerase IIacts upstream of or withinUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0045944 · evidence & context
  • ECO:0000314 PMID:12594207 ↗ IDA · MGI · 20250923
    qualifier: acts_upstream_of_or_within
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0043123", "relation": "part_of"}]}]
All recorded function and process assertions (101)
lipopolysaccharide bindingenablesUniProtKB:O00206
GO
GO:0001530 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20200401
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN002808115"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3870"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O00206"}]}]
  • ECO:0000303 PMID:10835634 ↗ NAS · UniProt · 20030103
    qualifier: enables
  • ECO:0000315 PMID:16514062 ↗ IMP · BHF-UCL · 20090204
    qualifier: enables
amyloid-beta bindingenablesUniProtKB:O00206
GO
GO:0001540 · evidence & context
  • ECO:0000305 PMID:20037584 ↗ IC · ARUK-UCL · 20181030
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "GO", "id": "1904646"}]}]
lipopolysaccharide immune receptor activityenablesUniProtKB:O00206
GO
GO:0001875 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20200401
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:96824"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002808115"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O00206"}]}]
  • ECO:0000314 PMID:19252480 ↗ IDA · UniProt · 20090602
    qualifier: enables
transmembrane signaling receptor activityenablesUniProtKB:O00206
GO
GO:0004888 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR017241"}]}]
  • ECO:0000303 PMID:11970998 ↗ NAS · UniProt · 20030103
    qualifier: enables
  • ECO:0000314 PMID:15618008 ↗ IDA · UniProt · 20241112
    qualifier: enables
signaling receptor bindingenablesUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0005102 · evidence & context
  • ECO:0000353 PMID:20037584 ↗ IPI · ARUK-UCL · 20170517
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P16671"}, {"db": "UniProtKB", "id": "Q9Y2C9"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "occurs_in"}, {"db": "GO", "id": "1904646", "relation": "part_of"}]}, {"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "occurs_in"}, {"db": "GO", "id": "0071404", "relation": "part_of"}]}]
protein bindingenablesUniProtKB:O00206
GO
GO:0005515 · evidence & context
  • ECO:0000353 PMID:11441107 ↗ IPI · UniProt · 20100301
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9H0E2"}]}]
  • ECO:0000353 PMID:11544529 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P58753"}]}]
  • ECO:0000353 PMID:12925853 ↗ IPI · HGNC-UCL · 20051010
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q6IA17"}]}]
  • ECO:0000353 PMID:15356101 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9NPH5"}]}]
  • ECO:0000353 PMID:15728506 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q99836"}]}]
  • ECO:0000353 PMID:15728506 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y6Y9"}]}]
  • ECO:0000353 PMID:16622205 ↗ IPI · MTBBASE · 20140825
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P9WGU1"}]}]
  • ECO:0000353 PMID:17064675 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9NPH5"}]}]
  • ECO:0000353 PMID:17126326 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q99836"}]}]
  • ECO:0000353 PMID:17258210 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P58753"}]}]
  • ECO:0000353 PMID:17258210 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86XR7"}]}]
  • ECO:0000353 PMID:17258210 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q99836"}]}]
  • ECO:0000353 PMID:17803912 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y6Y9"}]}]
  • ECO:0000353 PMID:19252480 ↗ IPI · UniProt · 20090602
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y6Y9"}]}]
  • ECO:0000353 PMID:19509286 ↗ IPI · BHF-UCL · 20110127
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P58753"}]}]
  • ECO:0000353 PMID:20037584 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2C9"}]}]
  • ECO:0000353 PMID:20547845 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y6Y9"}]}]
  • ECO:0000353 PMID:21383675 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P11226"}]}]
  • ECO:0000353 PMID:21829704 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P58753"}]}]
  • ECO:0000353 PMID:21829704 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86XR7"}]}]
  • ECO:0000353 PMID:21829704 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q99836"}]}]
  • ECO:0000353 PMID:21903422 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P58753"}]}]
  • ECO:0000353 PMID:21903422 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86XR7"}]}]
  • ECO:0000353 PMID:25187624 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O15389"}]}]
  • ECO:0000353 PMID:25187624 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O43699-3"}]}]
  • ECO:0000353 PMID:25187624 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y336"}]}]
  • ECO:0000353 PMID:29150600 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P24821"}]}]
  • ECO:0000353 PMID:29190778 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q96A54"}]}]
  • ECO:0000353 PMID:36232715 ↗ IPI · UniProt · 20231009
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8IUC6"}]}]
  • ECO:0000353 PMID:36232715 ↗ IPI · UniProt · 20231009
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q96DA0"}]}]
  • ECO:0000353 PMID:36232715 ↗ IPI · UniProt · 20231009
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q99836"}]}]
signaling receptor activityenablesUniProtKB:O00206
GO
GO:0038023 · evidence & context
signaling receptor activityenablesUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0038023 · evidence & context
  • ECO:0000314 PMID:15618008 ↗ IDA · UniProt · 20220708
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0034142", "relation": "part_of"}, {"db": "GO", "id": "0060090", "relation": "directly_positively_regulates"}]}]
signaling receptor activityenablesUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0038023 · evidence & context
  • ECO:0000314 PMID:15618008 ↗ IDA · UniProt · 20230523
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0034142", "relation": "part_of"}, {"db": "UniProtKB", "id": "Q99836", "relation": "has_input"}, {"db": "GO", "id": "0060090", "relation": "directly_positively_regulates"}]}]
signaling receptor activityenablesUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0038023 · evidence & context
  • ECO:0000314 PMID:16751103 ↗ IDA · UniProt · 20230317
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P58753", "relation": "has_input"}, {"db": "GO", "id": "0035591", "relation": "directly_positively_regulates"}]}]
signaling receptor activityenablesUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0038023 · evidence & context
  • ECO:0000314 PMID:16751103 ↗ IDA · UniProt · 20240304
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P58753", "relation": "has_input"}]}]
signaling receptor activityenablesUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0038023 · evidence & context
  • ECO:0000314 PMID:18222170 ↗ IDA · UniProt · 20230322
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0034142", "relation": "part_of"}, {"db": "GO", "id": "0010008", "relation": "occurs_in"}, {"db": "UniProtKB", "id": "P58753", "relation": "has_input"}]}]
identical protein bindingenablesUniProtKB:O00206
GO
GO:0042802 · evidence & context
  • ECO:0000353 PMID:23059983 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O00206"}]}]
  • ECO:0000353 PMID:23155421 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O00206"}]}]
  • ECO:0000353 PMID:31319868 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O00206"}]}]
protein heterodimerization activityenablesUniProtKB:O00206
GO
GO:0046982 · evidence & context
  • ECO:0000353 PMID:20037584 ↗ IPI · ARUK-UCL · 20170517
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2C9"}]}]
toll-like receptor signaling pathwayinvolved inUniProtKB:O00206
GO
GO:0002224 · evidence & context
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00087828"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR017241"}]}]
  • ECO:0000314 PMID:14607928 ↗ IDA · ComplexPortal · 20240827
    qualifier: involved_in
wound healing involved in inflammatory responseinvolved inUniProtKB:O00206
GO
GO:0002246 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
MyD88-dependent toll-like receptor signaling pathwayinvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0002755 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20170517
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000235", "relation": "occurs_in"}, {"db": "GO", "id": "0002269", "relation": "positively_regulates"}, {"db": "GO", "id": "0071404", "relation": "part_of"}]}]
MyD88-dependent toll-like receptor signaling pathwayinvolved inUniProtKB:O00206
GO
GO:0002755 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20230508
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:96824"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002808115"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O00206"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000314 PMID:20037584 ↗ IDA · ComplexPortal · 20240823
    qualifier: involved_in
  • ECO:0000314 PMID:38670073 ↗ IDA · UniProt · 20241125
    qualifier: involved_in
phagocytosisinvolved inUniProtKB:O00206
GO
GO:0006909 · evidence & context
inflammatory responseinvolved inUniProtKB:O00206
GO
GO:0006954 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20260204
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:96824"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002808115"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3870"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O00206"}]}]
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00045028"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000314 PMID:20037584 ↗ IDA · UniProt · 20240304
    qualifier: involved_in
immune responseinvolved inUniProtKB:O00206
GO
GO:0006955 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR017241"}]}]
  • ECO:0000304 PMID:10426995 ↗ TAS · PINC · 20091112
    qualifier: involved_in
signal transductioninvolved inUniProtKB:O00206
GO
GO:0007165 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR000157"}]}]
positive regulation of platelet activationinvolved inUniProtKB:O00206
GO
GO:0010572 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000250 PMID:16514062 ↗ ISS · BHF-UCL · 20090204
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
positive regulation of gene expressioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0010628 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20170517
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000129", "relation": "occurs_in"}, {"db": "UniProtKB", "id": "P01584", "relation": "has_input"}, {"db": "GO", "id": "1904646", "relation": "part_of"}]}]
positive regulation of gene expressioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0010628 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20170517
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000129", "relation": "occurs_in"}, {"db": "UniProtKB", "id": "P13501", "relation": "has_input"}]}]
positive regulation of gene expressioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0010628 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20170517
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000235", "relation": "occurs_in"}, {"db": "GO", "id": "0002269", "relation": "positively_regulates"}, {"db": "GO", "id": "0071404", "relation": "part_of"}, {"db": "UniProtKB", "id": "P01584", "relation": "has_input"}]}]
positive regulation of gene expressioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0010628 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20170517
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000235", "relation": "occurs_in"}, {"db": "GO", "id": "0002269", "relation": "positively_regulates"}, {"db": "GO", "id": "0071404", "relation": "part_of"}, {"db": "UniProtKB", "id": "P09341", "relation": "has_input"}]}, {"connectedXrefs": [{"db": "CL", "id": "0000235", "relation": "occurs_in"}, {"db": "GO", "id": "0002269", "relation": "positively_regulates"}, {"db": "GO", "id": "0071404", "relation": "part_of"}, {"db": "UniProtKB", "id": "P19875", "relation": "has_input"}]}, {"connectedXrefs": [{"db": "CL", "id": "0000235", "relation": "occurs_in"}, {"db": "GO", "id": "0002269", "relation": "positively_regulates"}, {"db": "GO", "id": "0071404", "relation": "part_of"}, {"db": "UniProtKB", "id": "P13501", "relation": "has_input"}]}]
positive regulation of gene expressioninvolved inUniProtKB:O00206
GO
GO:0010628 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
positive regulation of gene expressioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0010628 · evidence & context
  • ECO:0000315 PMID:23817958 ↗ IMP · UniProt · 20150616
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000134", "relation": "occurs_in"}, {"db": "UniProtKB", "id": "O00182", "relation": "has_input"}]}]
detection of fungusinvolved inUniProtKB:O00206
GO
GO:0016046 · evidence & context
response to lipopolysaccharideinvolved inUniProtKB:O00206
GO
GO:0032496 · evidence & context
  • ECO:0000314 PMID:14607928 ↗ IDA · ComplexPortal · 20240827
    qualifier: involved_in
  • ECO:0000305 PMID:16514062 ↗ IC · BHF-UCL · 20090204
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "GO", "id": "0001530"}]}]
detection of lipopolysaccharideinvolved inUniProtKB:O00206
GO
GO:0032497 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20230508
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:96824"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002808115"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O00206"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000314 PMID:19252480 ↗ IDA · UniProt · 20090602
    qualifier: involved_in
negative regulation of type II interferon productioninvolved inUniProtKB:O00206
GO
GO:0032689 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100311
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
negative regulation of interleukin-17 productioninvolved inUniProtKB:O00206
GO
GO:0032700 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100311
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
negative regulation of interleukin-23 productioninvolved inUniProtKB:O00206
GO
GO:0032707 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100130
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
negative regulation of interleukin-6 productioninvolved inUniProtKB:O00206
GO
GO:0032715 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100311
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
negative regulation of tumor necrosis factor productioninvolved inUniProtKB:O00206
GO
GO:0032720 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100311
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
positive regulation of chemokine productioninvolved inUniProtKB:O00206
GO
GO:0032722 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000314 PMID:19740627 ↗ IDA · BHF-UCL · 20091112
    qualifier: involved_in
positive regulation of interferon-alpha productioninvolved inUniProtKB:O00206
GO
GO:0032727 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100304
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
positive regulation of interferon-beta productioninvolved inUniProtKB:O00206
GO
GO:0032728 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100304
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
positive regulation of type II interferon productioninvolved inUniProtKB:O00206
GO
GO:0032729 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100130
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
positive regulation of interleukin-1 beta productioninvolved inUniProtKB:O00206
GO
GO:0032731 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · UniProt · 20151030
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000314 PMID:11432859 ↗ IDA · UniProt · 20170530
    qualifier: involved_in
positive regulation of interleukin-1 productioninvolved inUniProtKB:O00206
GO
GO:0032732 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100304
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
positive regulation of interleukin-10 productioninvolved inUniProtKB:O00206
GO
GO:0032733 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100304
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
positive regulation of interleukin-12 productioninvolved inUniProtKB:O00206
GO
GO:0032735 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100304
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000314 PMID:15027902 ↗ IDA · UniProt · 20071228
    qualifier: involved_in
positive regulation of interleukin-6 productioninvolved inUniProtKB:O00206
GO
GO:0032755 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000314 PMID:19740627 ↗ IDA · BHF-UCL · 20091112
    qualifier: involved_in
positive regulation of interleukin-6 productioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0032755 · evidence & context
  • ECO:0000315 PMID:21329689 ↗ IMP · ARUK-UCL · 20200409
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000517", "relation": "occurs_in"}]}]
positive regulation of interleukin-6 productioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0032755 · evidence & context
  • ECO:0000315 PMID:30321456 ↗ IMP · ARUK-UCL · 20190628
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "occurs_in"}]}]
positive regulation of interleukin-8 productioninvolved inUniProtKB:O00206
GO
GO:0032757 · evidence & context
positive regulation of interleukin-8 productioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0032757 · evidence & context
  • ECO:0000314 PMID:21329689 ↗ IDA · ARUK-UCL · 20200409
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000517", "relation": "occurs_in"}]}]
positive regulation of tumor necrosis factor productioninvolved inUniProtKB:O00206
GO
GO:0032760 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100304
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000314 PMID:17951129 ↗ IDA · UniProt · 20071228
    qualifier: involved_in
positive regulation of tumor necrosis factor productioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0032760 · evidence & context
  • ECO:0000315 PMID:30321456 ↗ IMP · ARUK-UCL · 20190628
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "occurs_in"}]}]
toll-like receptor 4 signaling pathwayinvolved inUniProtKB:O00206
GO
GO:0034142 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20230508
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:96824"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002808115"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O00206"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000314 PMID:10196138 ↗ IDA · UniProt · 20230317
    qualifier: involved_in
  • ECO:0000314 PMID:15618008 ↗ IDA · UniProt · 20220708
    qualifier: involved_in
  • ECO:0000314 PMID:18222170 ↗ IDA · UniProt · 20230322
    qualifier: involved_in
TRIF-dependent toll-like receptor signaling pathwayinvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0035666 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20170517
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000235", "relation": "occurs_in"}, {"db": "GO", "id": "0002269", "relation": "positively_regulates"}, {"db": "GO", "id": "0071404", "relation": "part_of"}]}]
TRIF-dependent toll-like receptor signaling pathwayinvolved inUniProtKB:O00206
GO
GO:0035666 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
cellular response to platelet-derived growth factor stimulusinvolved inUniProtKB:O00206
GO
GO:0036120 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
T-helper 1 type immune responseinvolved inUniProtKB:O00206
GO
GO:0042088 · evidence & context
macrophage activationinvolved inUniProtKB:O00206
GO
GO:0042116 · evidence & context
defense response to bacteriuminvolved inUniProtKB:O00206
GO
GO:0042742 · evidence & context
defense response to bacteriuminvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0042742 · evidence & context
  • ECO:0000316 PMID:30321456 ↗ IGI · ARUK-UCL · 20190628
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "RNAcentral", "id": "URS000026261D_9606"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "occurs_in"}]}]
positive regulation of macrophage activationinvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0043032 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20170628
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0050729", "relation": "part_of"}]}]
positive regulation of macrophage activationinvolved inUniProtKB:O00206
GO
GO:0043032 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
positive regulation of canonical NF-kappaB signal transductioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0043123 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · UniProt · 20241112
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:96824"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1900017", "relation": "part_of"}]}]
  • ECO:0000314 PMID:16968406 ↗ IDA · UniProt · 20241112
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1900017", "relation": "part_of"}]}]
positive regulation of canonical NF-kappaB signal transductioninvolved inUniProtKB:O00206
GO
GO:0043123 · evidence & context
  • ECO:0000314 PMID:19740627 ↗ IDA · BHF-UCL · 20250215
    qualifier: involved_in
  • ECO:0000316 PMID:20037584 ↗ IGI · ARUK-UCL · 20240201
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P05067-PRO_0000000092"}, {"db": "UniProtKB", "id": "P16671"}, {"db": "UniProtKB", "id": "Q9Y2C9"}]}]
positive regulation of canonical NF-kappaB signal transductioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0043123 · evidence & context
  • ECO:0000316 PMID:20037584 ↗ IGI · ARUK-UCL · 20240201
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P16671"}, {"db": "UniProtKB", "id": "Q9Y2C9"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000235", "relation": "occurs_in"}, {"db": "GO", "id": "0002269", "relation": "positively_regulates"}, {"db": "GO", "id": "0071404", "relation": "part_of"}]}]
innate immune responseinvolved inUniProtKB:O00206
GO
GO:0045087 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000304 PMID:15356140 ↗ TAS · BHF-UCL · 20100304
    qualifier: involved_in
  • ECO:0005547 PMID:33576548 ↗ NAS · ComplexPortal · 20240827
    qualifier: involved_in
leukocyte activationinvolved inUniProtKB:O00206
GO
GO:0045321 · evidence & context
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00091994"}]}]
positive regulation of nitric oxide biosynthetic processinvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0045429 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20230517
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1904646", "relation": "part_of"}, {"db": "CL", "id": "0000129", "relation": "occurs_in"}]}]
negative regulation of osteoclast differentiationinvolved inUniProtKB:O00206
GO
GO:0045671 · evidence & context
positive regulation of transcription by RNA polymerase IIinvolved inUniProtKB:O00206
GO
GO:0045944 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100304
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
regulation of inflammatory responseinvolved inUniProtKB:O00206
GO
GO:0050727 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
positive regulation of inflammatory responseinvolved inUniProtKB:O00206
GO
GO:0050729 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000314 PMID:19740627 ↗ IDA · BHF-UCL · 20250215
    qualifier: involved_in
positive regulation of inflammatory responseinvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0050729 · evidence & context
  • ECO:0000315 PMID:21329689 ↗ IMP · ARUK-UCL · 20190701
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000517", "relation": "occurs_in"}]}]
defense response to Gram-negative bacteriuminvolved inUniProtKB:O00206
GO
GO:0050829 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20200401
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:96824"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002808115"}]}]
  • ECO:0000305 PMID:16514062 ↗ IC · BHF-UCL · 20090204
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "GO", "id": "0001530"}]}]
intestinal epithelial structure maintenanceinvolved inUniProtKB:O00206
GO
GO:0060729 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100311
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
negative regulation of ERK1 and ERK2 cascadeinvolved inUniProtKB:O00206
GO
GO:0070373 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100311
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
cellular response to lipopolysaccharideinvolved inUniProtKB:O00206
GO
GO:0071222 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20100311
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000314 PMID:11432859 ↗ IDA · UniProt · 20170530
    qualifier: involved_in
cellular response to lipopolysaccharideinvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0071222 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20181012
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000129", "relation": "occurs_in"}]}]
cellular response to lipopolysaccharideinvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0071222 · evidence & context
  • ECO:0000316 PMID:30321456 ↗ IGI · ARUK-UCL · 20190628
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "RNAcentral", "id": "URS000026261D_9606"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "occurs_in"}]}]
cellular response to mechanical stimulusinvolved inUniProtKB:O00206
GO
GO:0071260 · evidence & context
cellular response to type II interferoninvolved inUniProtKB:O00206
GO
GO:0071346 · evidence & context
negative regulation of cold-induced thermogenesisinvolved inUniProtKB:O00206
GO
GO:0120163 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000250 PMID:26370079 ↗ ISS · YuBioLab · 20180612
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
cellular response to oxidised low-density lipoprotein particle stimulusinvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:0140052 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20170703
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000235", "relation": "occurs_in"}, {"db": "GO", "id": "1900017", "relation": "part_of"}]}]
cellular response to oxidised low-density lipoprotein particle stimulusinvolved inUniProtKB:O00206
GO
GO:0140052 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000314 PMID:20037584 ↗ IDA · ComplexPortal · 20240823
    qualifier: involved_in
positive regulation of cytokine production involved in inflammatory responseinvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:1900017 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20170517
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000235", "relation": "occurs_in"}]}]
positive regulation of cytokine production involved in inflammatory responseinvolved inUniProtKB:O00206
GO
GO:1900017 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000314 PMID:16968406 ↗ IDA · UniProt · 20241112
    qualifier: involved_in
positive regulation of cytokine production involved in inflammatory responseinvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:1900017 · evidence & context
  • ECO:0000315 PMID:30321456 ↗ IMP · ARUK-UCL · 20190628
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "occurs_in"}]}]
positive regulation of NLRP3 inflammasome complex assemblyinvolved inUniProtKB:O00206
GO
GO:1900227 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · UniProt · 20151030
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
positive regulation of reactive oxygen species biosynthetic processinvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:1903428 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20170517
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000235", "relation": "occurs_in"}, {"db": "GO", "id": "0002269", "relation": "positively_regulates"}, {"db": "GO", "id": "0071404", "relation": "part_of"}]}]
positive regulation of reactive oxygen species biosynthetic processinvolved inUniProtKB:O00206
GO
GO:1903428 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
positive regulation of cellular response to macrophage colony-stimulating factor stimulusinvolved inUniProtKB:O00206
GO
GO:1903974 · evidence & context
positive regulation of matrix metallopeptidase secretioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:1904466 · evidence & context
  • ECO:0000315 PMID:21329689 ↗ IMP · ARUK-UCL · 20190701
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P14780", "relation": "regulates_transport_of"}, {"db": "CL", "id": "0000517", "relation": "occurs_in"}]}]
cellular response to amyloid-betainvolved inUniProtKB:O00206
GO
GO:1904646 · evidence & context
  • ECO:0000314 PMID:20037584 ↗ IDA · ComplexPortal · 20240823
    qualifier: involved_in
  • ECO:0000316 PMID:20037584 ↗ IGI · ARUK-UCL · 20170517
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P16671"}, {"db": "UniProtKB", "id": "Q9Y2C9"}]}]
positive regulation of chemokine (C-X-C motif) ligand 2 productioninvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:2000343 · evidence & context
  • ECO:0000315 PMID:21329689 ↗ IMP · ARUK-UCL · 20200409
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000517", "relation": "occurs_in"}]}]
positive regulation of extrinsic apoptotic signaling pathwayinvolved inUniProtKB:O00206 · Context-qualified assertion; see evidence
GO
GO:2001238 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20230301
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000540", "relation": "occurs_in"}, {"db": "CL", "id": "0000129", "relation": "occurs_in"}]}]
positive regulation of extrinsic apoptotic signaling pathwayinvolved inUniProtKB:O00206
GO
GO:2001238 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
02

Names & Taxonomy

Recommended name
Toll-like receptor 4
Gene
TLR4
Accession / entry
O00206 · TLR4_HUMAN
Species
Homo sapiens · NCBI 9606
Recorded aliases
hToll
Full taxonomy & recorded names

Eukaryota → Metazoa → Chordata → Craniata → Vertebrata → Euteleostomi → Mammalia → Eutheria → Euarchontoglires → Primates → Haplorrhini → Catarrhini → Hominidae → Homo

{
  "names": {
    "recommendedName": {
      "fullName": {
        "value": "Toll-like receptor 4"
      }
    },
    "alternativeNames": [
      {
        "fullName": {
          "value": "hToll"
        }
      }
    ],
    "cdAntigenNames": [
      {
        "value": "CD284"
      }
    ],
    "flag": "Precursor"
  },
  "genes": [
    {
      "geneName": {
        "value": "TLR4"
      }
    }
  ]
}
03

Subcellular Location

UniProt locations and GO cellular-component assertions. Relations and contexts remain distinct; “part of” is not automatically a residence claim.

Cell membraneReported location

Single-pass type I membrane protein

Upon complex formation with CD36 and TLR6, internalized through dynamin-dependent endocytosis [29]. Colocalizes with RFTN1 at cell membrane and then together with RFTN1 moves to endosomes, upon lipopolysaccharide stimulation. Co-localizes with ZG16B/PAUF at the cell membrane of pancreatic cancer cells [42]

UniProt
Experimental evidence 9 publications
Evidence & references
Early endosomeReported location

Upon complex formation with CD36 and TLR6, internalized through dynamin-dependent endocytosis [29]. Colocalizes with RFTN1 at cell membrane and then together with RFTN1 moves to endosomes, upon lipopolysaccharide stimulation. Co-localizes with ZG16B/PAUF at the cell membrane of pancreatic cancer cells [42]

UniProt
Experimental evidence 1 publication
Evidence & references
Cell projection, ruffleReported location

Upon complex formation with CD36 and TLR6, internalized through dynamin-dependent endocytosis [29]. Colocalizes with RFTN1 at cell membrane and then together with RFTN1 moves to endosomes, upon lipopolysaccharide stimulation. Co-localizes with ZG16B/PAUF at the cell membrane of pancreatic cancer cells [42]

UniProt
By similarity
Evidence & references
  • ECO:0000250 UniProtKB:Q9QUK6
plasma membraneis active in
GO
2 publications
Evidence & references
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20260529
    qualifier: is_active_in
    withFrom: [{"connectedXrefs": [{"db": "FB", "id": "FBgn0262473"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1341295"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1341296"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1346060"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:2156367"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:96824"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002808045"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O00206"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O60602"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O60603"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q15399"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9GL65"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2C9"}]}]
  • ECO:0000314 PMID:12055629 ↗ IDA · UniProt · 20241112
    qualifier: is_active_in
  • ECO:0000314 PMID:38670073 ↗ IDA · UniProt · 20241125
    qualifier: is_active_in
endosome membraneis active in
GO
1 publication
Evidence & references
rufflelocated in
GO
Evidence & references
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0300"}]}]
phagocytic cuplocated in
GO
1 publication
Evidence & references
cytoplasmlocated in
GO
1 publication
Evidence & references
All recorded location assertions (21)
cytoplasmlocated in

UniProtKB:O00206 · [{"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "part_of"}, {"db": "CHEBI", "id": "64647", "relation": "coincident_with"}, {"db": "GO", "id": "0006897", "relation": "existence_overlaps"}]}, {"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "part_of"}, {"db": "CHEBI", "id": "60151", "relation": "coincident_with"}, {"db": "GO", "id": "0006897", "relation": "existence_overlaps"}]}]

GO
1 publication
Evidence & references
  • ECO:0000353 PMID:20037584 ↗ IPI · ARUK-UCL · 20181214
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P16671"}, {"db": "UniProtKB", "id": "Q9Y2C9"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "part_of"}, {"db": "CHEBI", "id": "64647", "relation": "coincident_with"}, {"db": "GO", "id": "0006897", "relation": "existence_overlaps"}]}, {"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "part_of"}, {"db": "CHEBI", "id": "60151", "relation": "coincident_with"}, {"db": "GO", "id": "0006897", "relation": "existence_overlaps"}]}]
early endosomelocated in
GO
Evidence & references
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0094"}]}]
plasma membranelocated in

UniProtKB:O00206 · [{"connectedXrefs": [{"db": "CL", "id": "0000129", "relation": "part_of"}, {"db": "GO", "id": "0071222", "relation": "part_of"}]}]

GO
By similarity
Evidence & references
  • ECO:0000250 GO_REF:0000024 ISS · ARUK-UCL · 20181012
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000129", "relation": "part_of"}, {"db": "GO", "id": "0071222", "relation": "part_of"}]}]
plasma membranelocated in
GO
Experimental evidence 10 publications
Evidence & references
  • ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115
    qualifier: located_in
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}, {"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0039"}]}]
  • ECO:0000314 PMID:11274165 ↗ IDA · UniProt · 20150716
    qualifier: located_in
  • ECO:0000314 PMID:16338228 ↗ IDA · UniProt · 20171005
    qualifier: located_in
  • ECO:0000269 PMID:17098818 ↗ EXP · UniProt · 20251027
    qualifier: located_in
  • ECO:0000314 PMID:19740627 ↗ IDA · BHF-UCL · 20091112
    qualifier: located_in
  • ECO:0000269 PMID:20037584 ↗ EXP · UniProt · 20251027
    qualifier: located_in
  • ECO:0000269 PMID:21393102 ↗ EXP · UniProt · 20251027
    qualifier: located_in
  • ECO:0005547 PMID:33576548 ↗ NAS · ComplexPortal · 20240827
    qualifier: located_in
  • ECO:0000314 PMID:36232715 ↗ IDA · UniProt · 20231009
    qualifier: located_in
  • ECO:0000269 PMID:36945827 ↗ EXP · UniProt · 20251027
    qualifier: located_in
  • ECO:0000269 PMID:9237759 ↗ EXP · UniProt · 20251027
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-166041 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-166072 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-166082 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-166091 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-166119 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-166284 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-166286 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-166362 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-166363 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2201293 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2201316 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2201322 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2262775 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2262777 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2559414 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5432825 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5432849 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5432852 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5602353 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5602383 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5602606 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-6805943 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-8869667 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-8870678 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-937022 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-937059 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-937079 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9707659 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9836227 TAS · Reactome · 20130528
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9921458 TAS · Reactome · 20130528
    qualifier: located_in
plasma membranelocated in

UniProtKB:O00206 · [{"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "part_of"}]}]

GO
1 publication
Evidence & references
  • ECO:0000314 PMID:15027902 ↗ IDA · UniProt · 20140812
    qualifier: located_in
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "part_of"}]}]
external side of plasma membranelocated in
GO
1 publication
Evidence & references
cell surfacelocated in

UniProtKB:O00206 · [{"connectedXrefs": [{"db": "CL", "id": "0002618", "relation": "part_of"}]}]

GO
1 publication
Evidence & references
  • ECO:0000314 PMID:25204797 ↗ IDA · UniProt · 20150402
    qualifier: located_in
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0002618", "relation": "part_of"}]}]
endosome membranelocated in
GO
Evidence & references
  • ECO:0000304 Reactome:R-HSA-166168 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-166175 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-166245 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-166271 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-168915 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-168921 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2201293 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2201338 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2213017 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2559568 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2562541 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2562564 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-2569057 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-450358 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5362486 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5362500 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-936947 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-936951 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-936952 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-936985 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-937029 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-937075 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9823904 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9823906 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9823910 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9823932 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9823934 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9823939 TAS · Reactome · 20120419
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9824882 TAS · Reactome · 20120419
    qualifier: located_in
membranelocated in
GO
Evidence & references
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00028763"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR017241"}]}]
perinuclear region of cytoplasmlocated in

UniProtKB:O00206 · [{"connectedXrefs": [{"db": "CL", "id": "0000451", "relation": "part_of"}]}]

GO
1 publication
Evidence & references
  • ECO:0000314 PMID:15027902 ↗ IDA · UniProt · 20140812
    qualifier: located_in
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000451", "relation": "part_of"}]}]
signaling receptor complexpart of
GO
2 publications
Evidence & references
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: part_of
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9QUK6"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000045770"}]}]
  • ECO:0000353 PMID:19252480 ↗ IPI · ComplexPortal · 20240827
    qualifier: part_of
  • ECO:0000353 PMID:20037584 ↗ IPI · ComplexPortal · 20240823
    qualifier: part_of
signaling receptor complexpart of

UniProtKB:O00206 · [{"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "part_of"}, {"db": "CHEBI", "id": "64647", "relation": "coincident_with"}, {"db": "GO", "id": "0005622", "relation": "part_of"}]}, {"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "part_of"}, {"db": "CHEBI", "id": "60151", "relation": "coincident_with"}, {"db": "GO", "id": "0005622", "relation": "part_of"}]}]

GO
1 publication
Evidence & references
  • ECO:0000353 PMID:20037584 ↗ IPI · ARUK-UCL · 20170517
    qualifier: part_of
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P16671"}, {"db": "UniProtKB", "id": "Q9Y2C9"}]}]
    extensions: [{"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "part_of"}, {"db": "CHEBI", "id": "64647", "relation": "coincident_with"}, {"db": "GO", "id": "0005622", "relation": "part_of"}]}, {"connectedXrefs": [{"db": "CL", "id": "0000576", "relation": "part_of"}, {"db": "CHEBI", "id": "60151", "relation": "coincident_with"}, {"db": "GO", "id": "0005622", "relation": "part_of"}]}]
lipopolysaccharide receptor complexpart of
GO
2 publications
Evidence & references
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20240305
    qualifier: part_of
    withFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN002808115"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O00206"}]}]
  • ECO:0000314 PMID:11274165 ↗ IDA · UniProt · 20150716
    qualifier: part_of
  • ECO:0000314 PMID:19252480 ↗ IDA · UniProt · 20090602
    qualifier: part_of

Membrane topology 3

Scroll across the table for evidence and actions.

3 recorded rows

FeaturePositionDescriptionEvidenceInspect
Topological domain24–631Extracellular
Sequence analysis
Evidence & references
  • ECO:0000255
601/608 residues mapped to 8WO1
Transmembrane632–652Helical
Sequence analysis
Evidence & references
  • ECO:0000255
No verified residues in this structure
Topological domain653–839Cytoplasmic
Sequence analysis
Evidence & references
  • ECO:0000255
No verified residues in this structure
04

Disease & Variants

Source annotations; a recorded variant is not automatically a clinical classification.

No annotation is recorded in this UniProt entry.

Polymorphism notes

Allele TLR4*B (Gly-299, Ile-399) is associated with a blunted response to inhaled LPS

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "10835634"
        }
      ],
      "value": "Allele TLR4*B (Gly-299, Ile-399) is associated with a blunted response to inhaled LPS"
    }
  ],
  "commentType": "POLYMORPHISM"
}

Natural variants 18

Scroll across the table for evidence and actions.

18 recorded rows

FeaturePositionDescriptionEvidenceInspect
T175AVAR_021977175in dbSNP:rs16906079
T → A
Evidence & references

No separate evidence record is supplied for this statement.

1/1 residues mapped to 8WO1
Q188RVAR_018729188in dbSNP:rs5030713
Q → R
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
C246SVAR_018730246in dbSNP:rs5030714
C → S
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
E287DVAR_074187287Natural variant
E → D
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
D299GVAR_012739299in allele TLR4*B; reduced LPS-response; associated with an increased risk for age-related macular degeneration in Caucasian carriers; dbSNP:rs4986790
D → G
Experimental evidence 5 publications
Evidence & references
1/1 residues mapped to 8WO1
C306WVAR_047563306in dbSNP:rs2770145
C → W
Evidence & references

No separate evidence record is supplied for this statement.

1/1 residues mapped to 8WO1
V310GVAR_047564310in dbSNP:rs2770144
V → G
Evidence & references

No separate evidence record is supplied for this statement.

1/1 residues mapped to 8WO1
N329SVAR_018731329in dbSNP:rs5030715
N → S
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
F342YVAR_020334342in dbSNP:rs5031050
F → Y
Evidence & references

No separate evidence record is supplied for this statement.

1/1 residues mapped to 8WO1
L385FVAR_037668385in dbSNP:rs11536884
L → F
Evidence & references

No separate evidence record is supplied for this statement.

1/1 residues mapped to 8WO1
T399IVAR_012740399in allele TLR4*B; reduced LPS-response; dbSNP:rs4986791
T → I
Experimental evidence 4 publications
Evidence & references
1/1 residues mapped to 8WO1
S400NVAR_020335400in dbSNP:rs4987233
S → N
Evidence & references

No separate evidence record is supplied for this statement.

1/1 residues mapped to 8WO1
F443LVAR_018732443in dbSNP:rs5030716
F → L
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
E474KVAR_018733474in dbSNP:rs5030718
E → K
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
Q510HVAR_018734510in dbSNP:rs5030719
Q → H
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
K694RVAR_018735694in dbSNP:rs5030722
K → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R763HVAR_018736763in dbSNP:rs5030723
R → H
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q834HVAR_018737834Natural variant
Q → H
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure

Laboratory mutagenesis 9

Scroll across the table for evidence and actions.

9 recorded rows

FeaturePositionDescriptionEvidenceInspect
H431A431Partially diminishes NF-kappa-B activation induced by Ni(2+). Strongly reduces NF-kappa-B activation induced by Ni(2+); when associated with A-456 or A-458.
H → A
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
H456A456Partially diminishes NF-kappa-B activation induced by Ni(2+). Strongly reduces NF-kappa-B activation induced by Ni(2+); when associated with A-431. Suppresses NF-kappa-B activation induced by Ni(2+); when associated with A-458.
H → A
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
H458A458Partially diminishes NF-kappa-B activation induced by Ni(2+). Strongly reduces NF-kappa-B activation induced by Ni(2+); when associated with A-431. Suppresses NF-kappa-B activation induced by Ni(2+); when associated with A-456.
H → A
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
N526A526Abolishes LPS-response and prevents the cell surface expression.
N → A
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
N575A575Abolishes LPS-response and prevents the cell surface expression.
N → A
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
E697R697Abolishes LPS-response.
E → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R710E710Abolishes LPS-response.
R → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
D711K711Abolishes LPS-response.
D → K
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
P714H / P714R / P714E714Abolishes MYD88-binding and LPS-response.
P → H, R, E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
05

PTM/Processing

N-Glycosylation of Asn-526 and Asn-575 by STT3A-containing OST-A complex is necessary for the expression of TLR4 on the cell surface and the LPS-response [15, 46]. Likewise, mutants lacking two or more of the other N-glycosylation sites were deficient in interaction with LPS [15, 46]

Experimental evidence 2 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11706042"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "38670073"
        }
      ],
      "value": "N-Glycosylation of Asn-526 and Asn-575 by STT3A-containing OST-A complex is necessary for the expression of TLR4 on the cell surface and the LPS-response (PubMed:11706042, PubMed:38670073). Likewise, mutants lacking two or more of the other N-glycosylation sites were deficient in interaction with LPS (PubMed:11706042, PubMed:38670073)"
    }
  ],
  "commentType": "PTM"
}

Phosphorylated on tyrosine residues by LYN after binding lipopolysaccharide

By similarity
Evidence & references
  • ECO:0000250 UniProtKB:Q9QUK6
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "Q9QUK6"
        }
      ],
      "value": "Phosphorylated on tyrosine residues by LYN after binding lipopolysaccharide"
    }
  ],
  "commentType": "PTM"
}

Ubiquitinated by RNF128 via 'Lys-28'-linked polyubiquitin chains, leading to proteasomal degradation

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "37344492"
        }
      ],
      "value": "Ubiquitinated by RNF128 via 'Lys-28'-linked polyubiquitin chains, leading to proteasomal degradation"
    }
  ],
  "commentType": "PTM"
}

Processed chains & precursor regions 2

Scroll across the table for evidence and actions.

2 recorded rows

FeaturePositionDescriptionEvidenceInspect
Signal1–23Signal
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
ChainPRO_000003472224–839Toll-like receptor 4
Evidence & references

No separate evidence record is supplied for this statement.

601/816 residues mapped to 8WO1

Modifications 15

Scroll across the table for evidence and actions.

15 recorded rows

FeaturePositionDescriptionEvidenceInspect
Glycosylation35N-linked (GlcNAc...) asparagine
Experimental evidence 3 publications
Evidence & references
1/1 residues mapped to 8WO1
Glycosylation173N-linked (GlcNAc...) asparagine
Experimental evidence 4 publications
Evidence & references
1/1 residues mapped to 8WO1
Glycosylation205N-linked (GlcNAc...) asparagine
Experimental evidence 3 publications
Evidence & references
1/1 residues mapped to 8WO1
Glycosylation282N-linked (GlcNAc...) asparagine
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
Glycosylation309N-linked (GlcNAc...) asparagine
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
Glycosylation497N-linked (GlcNAc...) asparagine
Experimental evidence 2 publications
Evidence & references
1/1 residues mapped to 8WO1
Glycosylation526N-linked (GlcNAc...) asparagine
Experimental evidence 3 publications
Evidence & references
1/1 residues mapped to 8WO1
Glycosylation575N-linked (GlcNAc...) asparagine
Experimental evidence 3 publications
Evidence & references
1/1 residues mapped to 8WO1
Glycosylation624N-linked (GlcNAc...) asparagine
Experimental evidence 1 publication
Evidence & references
1/1 residues mapped to 8WO1
Glycosylation630N-linked (GlcNAc...) asparagine
Sequence analysis
Evidence & references
  • ECO:0000255
No verified residues in this structure
Disulfide bond29, 40Disulfide bond
Experimental evidence 2 publications
Evidence & references
2/2 residues mapped to 8WO1
Disulfide bond281, 306Disulfide bond
Experimental evidence 1 publication
Evidence & references
2/2 residues mapped to 8WO1
Disulfide bond390, 391Disulfide bond
Experimental evidence 1 publication
Evidence & references
2/2 residues mapped to 8WO1
Disulfide bond583, 609Disulfide bond
Experimental evidence 1 publication
Evidence & references
2/2 residues mapped to 8WO1
Disulfide bond585, 627Disulfide bond
Experimental evidence 1 publication
Evidence & references
2/2 residues mapped to 8WO1
06

Expression

Highly expressed in placenta, spleen and peripheral blood leukocytes [1, 2]. Detected in monocytes, macrophages, dendritic cells and several types of T-cells [37, 1]. Expressed in pancreatic cancer cells but not in normal pancreatic cells (at protein level) [42]

Experimental evidence 4 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "27022195"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "36232715"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "9237759"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "9435236"
        }
      ],
      "value": "Highly expressed in placenta, spleen and peripheral blood leukocytes (PubMed:9237759, PubMed:9435236). Detected in monocytes, macrophages, dendritic cells and several types of T-cells (PubMed:27022195, PubMed:9237759). Expressed in pancreatic cancer cells but not in normal pancreatic cells (at protein level) (PubMed:36232715)"
    }
  ],
  "commentType": "TISSUE SPECIFICITY"
}

Induction

By LPS in plasmacytoid dendritic cells

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15265881"
        }
      ],
      "value": "By LPS in plasmacytoid dendritic cells"
    }
  ],
  "commentType": "INDUCTION"
}
07

Interaction

Documented interaction partners

UniProt’s filtered IntAct records. Experiment counts describe reported experiments, not binding strength or independent publications. Separate products remain separate rows.

15 records
Partner / productSpeciesExperimentsEvidence & actions
ADIPOR1Q96A54With O00206Homo sapiens2
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: Q96A54. Reported experiment count: 2.

Open protein ↗
LY96Q9Y6Y9With O00206Homo sapiens7
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: Q9Y6Y9. Reported experiment count: 7.

Open protein ↗
MBL2P11226With O00206Homo sapiens2
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: P11226. Reported experiment count: 2.

Open protein ↗
MYD88Q99836With O00206Homo sapiens4
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: Q99836. Reported experiment count: 4.

Open protein ↗
NOX4Q9NPH5With O00206Homo sapiens4
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: Q9NPH5. Reported experiment count: 4.

Open protein ↗
SIGLEC5O15389With O00206Homo sapiens2
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: O15389. Reported experiment count: 2.

Open protein ↗
SIGLEC6O43699-3With O00206Homo sapiens2
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: O43699-3. Reported experiment count: 2.

Open protein ↗
SIGLEC9Q9Y336With O00206Homo sapiens2
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: Q9Y336. Reported experiment count: 2.

Open protein ↗
TICAM2Q86XR7With O00206Homo sapiens3
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: Q86XR7. Reported experiment count: 3.

Open protein ↗
TIRAPP58753With O00206Homo sapiens6
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: P58753. Reported experiment count: 6.

Open protein ↗
TLR4O00206With O00206Homo sapiens3
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: O00206. Reported experiment count: 3.

Open protein ↗
TLR6Q9Y2C9With O00206Homo sapiens2
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: Q9Y2C9. Reported experiment count: 2.

Open protein ↗
TNCP24821With O00206Homo sapiens4
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206. Partner: P24821. Reported experiment count: 4.

Open protein ↗
LY96Q9Y6Y9With O00206-1Homo sapiens5
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206-1. Partner: Q9Y6Y9. Reported experiment count: 5.

Open protein ↗
DERP2P49278With O00206-1Dermatophagoides pteronyssinusCross-species3
IntAct evidence

Pair evidence in IntAct ↗

Source product: O00206-1. Partner: P49278. Reported experiment count: 3.

Open protein ↗

Complex membership & assembly descriptions

Co-membership does not by itself prove direct binding between every pair.

LY96-TLR4 toll-like receptor complex CPX-2545 Complex Portal

Homo sapiens; 9606 · Heterotetramer

Evidence: physical interaction evidence

  • LY96 · Q9Y6Y9 · minValue: 2, maxValue: 2
  • TLR4 · O00206 · minValue: 2, maxValue: 2

Type I membrane receptor that plays a crucial role in innate immunity by recognizing conserved patterns in diverse microbial molecules including lipoproteins, lipopeptides, lipopolysaccharide, flagellin, and nucleic acids. In the early step of bacterial infection, serum lipopolysaccharide (LPS, CHEBI:16412) binds to the N-terminal of LBP (P18428), LPS is then presented to CD14 (P08571) and transferred to LY96 or the LY96-TLR4 toll-like receptor complex. This induces the dimerization of TLR4 TIR domains, initiating CD14-dependent TLR4 endocytosis, and TICAM1/TRIF(Q8IUC6)-dependent signal transduction to promote inflammation caused by LPS.

Source & references ↗
TLR4-TLR6 toll-like receptor complex CPX-945 Complex Portal

Homo sapiens; 9606 · Heterodimer

Evidence: physical interaction evidence

  • TLR6 · Q9Y2C9 · minValue: 1, maxValue: 1
  • TLR4 · O00206 · minValue: 1, maxValue: 1

Type I membrane receptor that plays a crucial role in innate immunity by recognizing conserved patterns in diverse microbial molecules including lipoproteins, lipopeptides, lipopolysaccharide, flagellin, and nucleic acids. Initiates innate immune activation of macrophages and microglia.through binding of atherogenic lipids susch as oxidised LDL (CHEBI:60151) or beta-amyloid 42 complex (CPX-1070) to a shared receptor, CD36 (P16671), that provides the proximal signalling event required for TLR4-TLR6 activation

Source & references ↗

UniProt subunit description

Belongs to the lipopolysaccharide (LPS) receptor, a multi-protein complex containing at least CD14, LY96 and TLR4 [14]. Binding to bacterial LPS leads to homodimerization. Interacts with LY96 via the extracellular domain [47, 48].

Interacts with MYD88 [42]. Interacts (via TIR domains) with TIRAP (By similarity). Interacts with TICAM2 [16, 36].

Interacts with NOX4 [19]. Interacts with CNPY3 (By similarity). Interacts with HSP90B1.

The interaction with both CNPY3 and HSP90B1 is required for proper folding in the endoplasmic reticulum. Interacts with MAP3K21; this interaction leads to negative regulation of TLR4 signaling [32]. Interacts with CD36, following CD36 stimulation by oxLDL or amyloid-beta 42, and forms a heterodimer with TLR6 [29].

The trimeric complex is internalized and triggers inflammatory response. LYN kinase activity facilitates TLR4-TLR6 heterodimerization and signal initiation. Interacts with TICAM1 in response to LPS in a WDFY1-dependent manner [36, 42].

Interacts with WDFY1 in response to LPS (By similarity). Interacts with SMPDL3B (By similarity). Interacts with CEACAM1; upon lipopolysaccharide stimulation, forms a complex including TLR4 and the phosphorylated form of SYK and CEACAM1, which in turn, recruits PTPN6 that dephosphorylates SYK, reducing the production of reactive oxygen species (ROS) and lysosome disruption, which in turn, reduces the activity of the inflammasome (By similarity).

Interacts with RFTN1; the interaction occurs in response to lipopolysaccharide stimulation [37]. Interacts with SCIMP; the interaction occurs in response to lipopolysaccharide stimulation and is enhanced by phosphorylation of SCIMP by LYN (By similarity). This interaction facilitates the phosphorylation of TLR4 by LYN which elicits a selective cytokine response in macrophages (By similarity).

Interacts with TRAF3IP3 [40]. Interacts with TREM1; this interaction enhances TLR4-mediated inflammatory response [24, 27]. Interacts with ZG16B/PAUF [42].

Interacts with CD82; this interaction inhibits TLR4-mediated signaling pathway [43]. Interacts with neutrophil recruitment protein from Aedes aegypti saliva; the interaction probably promotes activation of canonical NF-kappa-B signaling in skin-resident macrophages and subsequent expression of neutrophil chemoattractants [45]. Interacts with CD180; this interaction inhibits TLR4-mediated signaling pathway upon ligand binding [21].

Interacts (via TIR domain) with NOC4L; the interaction results in impaired TLR4 endocytosis and inhibition of the TICAM1/TRIF signaling pathway (By similarity)

By similarityExperimental evidence 17 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "Q9QUK6"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11274165"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "14519765"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15356101"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15852007"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17098818"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17803912"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19252480"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20037584"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20865800"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "21393102"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "21602844"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "25736436"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "27022195"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "30573680"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "36232715"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "36945827"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "38378891"
        }
      ],
      "value": "Belongs to the lipopolysaccharide (LPS) receptor, a multi-protein complex containing at least CD14, LY96 and TLR4 (PubMed:11274165). Binding to bacterial LPS leads to homodimerization. Interacts with LY96 via the extracellular domain (PubMed:17803912, PubMed:19252480). Interacts with MYD88 (PubMed:36232715). Interacts (via TIR domains) with TIRAP (By similarity). Interacts with TICAM2 (PubMed:14519765, PubMed:25736436). Interacts with NOX4 (PubMed:15356101). Interacts with CNPY3 (By similarity). Interacts with HSP90B1. The interaction with both CNPY3 and HSP90B1 is required for proper folding in the endoplasmic reticulum. Interacts with MAP3K21; this interaction leads to negative regulation of TLR4 signaling (PubMed:21602844). Interacts with CD36, following CD36 stimulation by oxLDL or amyloid-beta 42, and forms a heterodimer with TLR6 (PubMed:20037584). The trimeric complex is internalized and triggers inflammatory response. LYN kinase activity facilitates TLR4-TLR6 heterodimerization and signal initiation. Interacts with TICAM1 in response to LPS in a WDFY1-dependent manner (PubMed:25736436, PubMed:36232715). Interacts with WDFY1 in response to LPS (By similarity). Interacts with SMPDL3B (By similarity). Interacts with CEACAM1; upon lipopolysaccharide stimulation, forms a complex including TLR4 and the phosphorylated form of SYK and CEACAM1, which in turn, recruits PTPN6 that dephosphorylates SYK, reducing the production of reactive oxygen species (ROS) and lysosome disruption, which in turn, reduces the activity of the inflammasome (By similarity). Interacts with RFTN1; the interaction occurs in response to lipopolysaccharide stimulation (PubMed:27022195). Interacts with SCIMP; the interaction occurs in response to lipopolysaccharide stimulation and is enhanced by phosphorylation of SCIMP by LYN (By similarity). This interaction facilitates the phosphorylation of TLR4 by LYN which elicits a selective cytokine response in macrophages (By similarity). Interacts with TRAF3IP3 (PubMed:30573680). Interacts with TREM1; this interaction enhances TLR4-mediated inflammatory response (PubMed:17098818, PubMed:21393102). Interacts with ZG16B/PAUF (PubMed:36232715). Interacts with CD82; this interaction inhibits TLR4-mediated signaling pathway (PubMed:36945827). Interacts with neutrophil recruitment protein from Aedes aegypti saliva; the interaction probably promotes activation of canonical NF-kappa-B signaling in skin-resident macrophages and subsequent expression of neutrophil chemoattractants (PubMed:38378891). Interacts with CD180; this interaction inhibits TLR4-mediated signaling pathway upon ligand binding (PubMed:15852007). Interacts (via TIR domain) with NOC4L; the interaction results in impaired TLR4 endocytosis and inhibition of the TICAM1/TRIF signaling pathway (By similarity)"
    }
  ],
  "commentType": "SUBUNIT"
}

(Microbial infection) In case of infection, interacts with uropathogenic E.coli protein TcpC

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "23569230"
        }
      ],
      "value": "(Microbial infection) In case of infection, interacts with uropathogenic E.coli protein TcpC"
    }
  ],
  "commentType": "SUBUNIT"
}

(Microbial infection) In case of infection, interacts with B.melitensis protein TcpB; TcpB abolishes the TLR4-TIRAP interaction in vitro

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "24265315"
        }
      ],
      "value": "(Microbial infection) In case of infection, interacts with B.melitensis protein TcpB; TcpB abolishes the TLR4-TIRAP interaction in vitro"
    }
  ],
  "commentType": "SUBUNIT"
}

(Microbial infection) Interacts with ebolavirus protein GP; this interaction leads to the production of pro-inflammatory cytokines and suppressor of cytokine signaling 1/SOCS1

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19846529"
        }
      ],
      "value": "(Microbial infection) Interacts with ebolavirus protein GP; this interaction leads to the production of pro-inflammatory cytokines and suppressor of cytokine signaling 1/SOCS1"
    }
  ],
  "commentType": "SUBUNIT"
}

Other association resources

Resource links only; their association networks and counts are not added to the partner table.

08

Structure

SELECTED EXPERIMENTAL STRUCTURE

8WO1 · Cryo-EM Structure of Human TLR4/MD-2/DLAM5 Complex

Method
Electron microscopy
Resolution
2.24 Å
Assembly 1
Hetero 4-mer · A2B2
Symmetry
C2
Deposited / released
06/10/2023 / 09/10/2024
Entry version
3.1 · 14/05/2025
839aa · full canonical protein
605aa · deposited protein construct(s)
601canonical residues verified in coordinates

Verified residue selection uses chain(s) A. Deposited construct lengths are per protein entity, not the full precursor or a total across assembly copies.

601/601 residues mapped to 8WO1

Components & chains

Chain labels below are mmCIF identifiers used by the viewer. Assembly membership does not establish direct binding.

ComponentIdentity / lengthChainsInspect
Toll-like receptor 4Protein / polymer · Entity 1Homo sapiensO00206605 aaA, B
Lymphocyte antigen 96Protein / polymer · Entity 2Homo sapiensQ9Y6Y9142 aaC, D
beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranoseGlycan · Entity 3GlyCosmos G15407YE ↗CCD BMA ↗ CCD NAG ↗
Component chemical diagrams · RCSB PDB

Individual sugar components; this is not a diagram of glycan linkages.

RCSB chemical diagram of BMA
BMA
RCSB chemical diagram of NAG
NAG
BMA · NAG3 sugar unitsE, F, H, I
2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranoseGlycan · Entity 4GlyCosmos G42666HT ↗CCD NAG ↗
Component chemical diagrams · RCSB PDB

Individual sugar components; this is not a diagram of glycan linkages.

RCSB chemical diagram of NAG
NAG
NAG2 sugar unitsG, J
2-acetamido-2-deoxy-beta-D-glucopyranoseLigand / ion · Entity 5CCD NAG ↗
Chemical diagram · RCSB PDB
RCSB chemical diagram of NAG
NAG
NAGK, L, N, O, Q, VAuthor: A, B, C, D
2-amino-2-deoxy-4-O-phosphono-alpha-D-glucopyranoseLigand / ion · Entity 6CCD GP4 ↗
Chemical diagram · RCSB PDB
RCSB chemical diagram of GP4
GP4
GP4M, PAuthor: A, B
(3R)-3-(dodecanoyloxy)tetradecanoic acidLigand / ion · Entity 7CCD 2IL ↗
Chemical diagram · RCSB PDB
RCSB chemical diagram of 2IL
2IL
2ILR, WAuthor: C, D
(3R)-3-(tetradecanoyloxy)tetradecanoic acidLigand / ion · Entity 8CCD 0IL ↗
Chemical diagram · RCSB PDB
RCSB chemical diagram of 0IL
0IL
0ILS, XAuthor: C, D
[(2~{R},3~{S},4~{R},5~{S})-2-(hydroxymethyl)-5-methoxy-4,6-bis(oxidanyl)oxan-3-yl] dihydrogen phosphateLigand / ion · Entity 9CCD X6N ↗
Chemical diagram · RCSB PDB
RCSB chemical diagram of X6N
X6N
X6NT, YAuthor: C, D
(3~{S})-3-decanoyloxytetradecanoic acidLigand / ion · Entity 10CCD A1L01 ↗
Chemical diagram · RCSB PDB
RCSB chemical diagram of A1L01
A1L01
A1L01U, ZAuthor: C, D

Chemical diagrams are recorded RCSB component depictions. Glycan names and source identifiers retain the recorded linkage information.

Structure validation

Recorded PDBe metrics describe model geometry. Percentiles compare with the archive; they are not probabilities of correctness. Missing metrics are not zero.

Clashscore7.25

Serious atomic overlaps per 1,000 atoms; lower is better.

Archive percentile: 37.3
Ramachandran outliers0.0%

Backbone conformations outside preferred regions; lower is better.

Archive percentile: 100.0
Side-chain outliers0.0%

Unusual side-chain conformations; lower is better.

Archive percentile: 100.0
Full validation report ↗

Publication

Structural insight into TLR4/MD-2 activation by synthetic LPS mimetics with distinct binding modes.

Paper date: 05/05/2025 · Read publication ↗

Structure references are from the dated source record. Opening another structure follows your existing Atlas account permissions.

Available structures 16

Scroll across the table for evidence and actions.

16 recorded rows

RecordEvidence typeMethodResolutionOpen
8WO1experimentalEM2.24 AOpen in Atlas ↗
4G8AexperimentalX-ray2.40 AOpen in Atlas ↗
9J03experimentalEM2.70 AOpen in Atlas ↗
8WTAexperimentalEM2.90 AOpen in Atlas ↗
3FXIexperimentalX-ray3.10 AOpen in Atlas ↗
2Z63experimentalX-ray2.00 AOpen in Atlas ↗
2Z66experimentalX-ray1.90 AOpen in Atlas ↗
2Z62experimentalX-ray1.70 AOpen in Atlas ↗
3UL7experimentalX-ray2.37 AOpen in Atlas ↗
3UL9experimentalX-ray2.45 AOpen in Atlas ↗
3UL8experimentalX-ray2.50 AOpen in Atlas ↗
2Z65experimentalX-ray2.70 AOpen in Atlas ↗
3ULAexperimentalX-ray3.60 AOpen in Atlas ↗
5NAMexperimentalNMR-Open in Atlas ↗
5NAOexperimentalNMR-Open in Atlas ↗
AF-O00206-F1predictedAlphaFoldNot applicableOpen in Atlas ↗
09

Family & Domains

The TIR domain mediates interaction with NOX4

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15356101"
        }
      ],
      "value": "The TIR domain mediates interaction with NOX4"
    }
  ],
  "commentType": "DOMAIN"
}

Belongs to the Toll-like receptor family

Curator inference
Evidence & references
  • ECO:0000305
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000305"
        }
      ],
      "value": "Belongs to the Toll-like receptor family"
    }
  ],
  "commentType": "SIMILARITY"
}

Domain architecture

Canonical sequence1839 aa

Canonical coordinates. Overlapping marks share a lane; individual records and evidence are in the tables below. Gaps in coverage are not selectable in 3D. Use the track links and tables for keyboard inspection.

Atlas domains, motifs & repeats 34

Scroll across the table for evidence and actions.

34 recorded rows

AnnotationPositionSource & interpretationInspect
Prokaryotic membrane lipoprotein lipid attachment site profilePS512571–20PROSITESignature match

Sequence-signature evidence; this does not independently establish function or processing.

In prokaryotes, membrane lipoproteins are synthesized with a precursor signal peptide, which is cleaved by a specific lipoprotein signal peptidase (signal peptidase II). The peptidase recognizes a conserved sequence and cuts upstream of a cysteine residue to which a glyceride-fatty acid lipid is attached.

Full source description

In prokaryotes, membrane lipoproteins are synthesized with a precursor signal peptide, which is cleaved by a specific lipoprotein signal peptidase (signal peptidase II). The peptidase recognizes a conserved sequence and cuts upstream of a cysteine residue to which a glyceride-fatty acid lipid is attached. Some of the proteins known to undergo such processing currently include (for recent listings see ): - Major outer membrane lipoprotein (murein-lipoproteins) (gene lpp). - Escherichia coli lipoprotein-28 (gene nlpA). - Escherichia coli lipoprotein-34 (gene nlpB). - Escherichia coli lipoprotein nlpC. - Escherichia coli lipoprotein nlpD. - Escherichia coli osmotically inducible lipoprotein B (gene osmB). - Escherichia coli osmotically inducible lipoprotein E (gene osmE). - Escherichia coli peptidoglycan-associated lipoprotein (gene pal). - Escherichia coli rare lipoproteins A and B (genes rplA and rplB). - Escherichia coli copper homeostasis protein cutF (or nlpE). - Escherichia coli plasmids traT proteins. - Escherichia coli Col plasmids lysis proteins. - A number of Bacillus beta-lactamases. - Bacillus subtilis periplasmic oligopeptide-binding protein (gene oppA). - Borrelia burgdorferi outer surface proteins A and B (genes ospA and ospB). - Borrelia hermsii variable major protein 21 (gene vmp21) and 7 (gene vmp7). - Chlamydia trachomatis outer membrane protein 3 (gene omp3). - Fibrobacter succinogenes endoglucanase cel-3. - Haemophilus influenzae proteins Pal and Pcp. - Klebsiella pullulunase (gene pulA). - Klebsiella pullulunase secretion protein pulS. - Mycoplasma hyorhinis protein p37. - Mycoplasma hyorhinis variant surface antigens A, B, and C (genes vlpABC). - Neisseria outer membrane protein H.8. - Pseudomonas aeruginosa lipopeptide (gene lppL). - Pseudomonas solanacearum endoglucanase egl. - Rhodopseudomonas viridis reaction center cytochrome subunit (gene cytC). - Rickettsia 17 Kd antigen. - Shigella flexneri invasion plasmid proteins mxiJ and mxiM. - Streptococcus pneumoniae oligopeptide transport protein A (gene amiA). - Treponema pallidium 34 Kd antigen. - Treponema pallidium membrane protein A (gene tmpA). - Vibrio harveyi chitobiase (gene chb). - Yersinia virulence plasmid protein yscJ. - Halocyanin from Natrobacterium pharaonis, a membrane associated copper- binding protein. This is the first archaebacterial protein known to be modified in such a fashion). From the precursor sequences of all these proteins, we derived a profile that starts at the beginning of the sequence and ends after the post-translationally modified cysteine.

Source entry ↗
No verified residues in this structure
LRR RegionCLUSTER_LRR_57_24757–247ALPHASUITEdomain

10 LRR repeats grouped into a tandem region.

191/191 residues mapped to 8WO1
Leucine-rich repeatIPR00161157–114INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats.

Source entry ↗
58/58 residues mapped to 8WO1
Leucine-rich repeat, typical subtypeIPR00359157–76INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. This entry represents a most populated subfamily of leucine-rich repeats.

Source entry ↗
20/20 residues mapped to 8WO1
Leucine-rich repeat, typical subtypeIPR00359177–100INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. This entry represents a most populated subfamily of leucine-rich repeats.

Source entry ↗
24/24 residues mapped to 8WO1
Leucine-rich repeat, typical subtypeIPR003591101–124INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. This entry represents a most populated subfamily of leucine-rich repeats.

Source entry ↗
24/24 residues mapped to 8WO1
LRR 4UNI_REPEAT_127_148127–148UNIPROTrepeat

LRR 4

Source entry ↗
22/22 residues mapped to 8WO1
Leucine-rich repeat, SDS22-like subfamilySM00365149–173SMARTdomain

No description available for this entry.

Source entry ↗
25/25 residues mapped to 8WO1
Leucine-rich repeat, typical subtypeIPR003591149–173INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. This entry represents a most populated subfamily of leucine-rich repeats.

Source entry ↗
25/25 residues mapped to 8WO1
Leucine-rich repeatIPR001611151–207INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats.

Source entry ↗
57/57 residues mapped to 8WO1
Leucine-rich repeat, SDS22-like subfamilySM00365174–195SMARTdomain

No description available for this entry.

Source entry ↗
22/22 residues mapped to 8WO1
Leucine-rich repeat, typical subtypeIPR003591174–195INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. This entry represents a most populated subfamily of leucine-rich repeats.

Source entry ↗
22/22 residues mapped to 8WO1
LEURICHRPTPR00019177–190PRINTSSignature match

Sequence-signature evidence; this does not independently establish function or processing.

No description available for this entry.

Source entry ↗
14/14 residues mapped to 8WO1
Leucine-rich repeat, typical subtypeIPR003591201–225INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. This entry represents a most populated subfamily of leucine-rich repeats.

Source entry ↗
25/25 residues mapped to 8WO1
LRR 8UNI_REPEAT_227_247227–247UNIPROTrepeat

LRR 8

Source entry ↗
21/21 residues mapped to 8WO1
LRR RegionCLUSTER_LRR_331_565331–565ALPHASUITEdomain

12 LRR repeats grouped into a tandem region.

235/235 residues mapped to 8WO1
LRR 9UNI_REPEAT_331_351331–351UNIPROTrepeat

LRR 9

Source entry ↗
21/21 residues mapped to 8WO1
LRR 10UNI_REPEAT_352_373352–373UNIPROTrepeat

LRR 10

Source entry ↗
22/22 residues mapped to 8WO1
Leucine-rich repeat, typical subtypeIPR003591372–393INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. This entry represents a most populated subfamily of leucine-rich repeats.

Source entry ↗
22/22 residues mapped to 8WO1
LEURICHRPTPR00019372–385PRINTSSignature match

Sequence-signature evidence; this does not independently establish function or processing.

No description available for this entry.

Source entry ↗
14/14 residues mapped to 8WO1
Leucine-rich repeat, SDS22-like subfamilySM00365398–420SMARTdomain

No description available for this entry.

Source entry ↗
23/23 residues mapped to 8WO1
Leucine-rich repeatIPR001611399–412INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats.

Source entry ↗
14/14 residues mapped to 8WO1
LRR 12UNI_REPEAT_400_422400–422UNIPROTrepeat

LRR 12

Source entry ↗
23/23 residues mapped to 8WO1
Leucine-rich repeat, SDS22-like subfamilySM00365421–442SMARTdomain

No description available for this entry.

Source entry ↗
22/22 residues mapped to 8WO1
Leucine-rich repeat, typical subtypeIPR003591421–444INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. This entry represents a most populated subfamily of leucine-rich repeats.

Source entry ↗
24/24 residues mapped to 8WO1
LRR 14UNI_REPEAT_448_456448–456UNIPROTrepeat

LRR 14

Source entry ↗
9/9 residues mapped to 8WO1
Leucine-rich repeat, typical subtypeIPR003591470–494INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. This entry represents a most populated subfamily of leucine-rich repeats.

Source entry ↗
25/25 residues mapped to 8WO1
Leucine-rich repeatIPR001611490–532INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats.

Source entry ↗
43/43 residues mapped to 8WO1
Leucine-rich repeat, SDS22-like subfamilySM00365495–516SMARTdomain

No description available for this entry.

Source entry ↗
22/22 residues mapped to 8WO1
Leucine-rich repeat, typical subtypeIPR003591495–518INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. This entry represents a most populated subfamily of leucine-rich repeats.

Source entry ↗
24/24 residues mapped to 8WO1
Leucine-rich repeat, typical subtypeIPR003591519–540INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. This entry represents a most populated subfamily of leucine-rich repeats.

Source entry ↗
22/22 residues mapped to 8WO1
LRR 18UNI_REPEAT_545_565545–565UNIPROTrepeat

LRR 18

Source entry ↗
21/21 residues mapped to 8WO1
Cysteine-rich flanking region, C-terminalIPR000483579–628INTERPROdomain

Leucine-rich repeats (LRR, see [interpro:IPR001611]) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.

Full source description

Leucine-rich repeats (LRR, see [interpro:IPR001611]) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions. Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. LRRs are often flanked by cysteine-rich domains: an N-terminal LRR domain ([interpro:IPR000372]) and a C-terminal LRR domain. This entry represents the C-terminal LRR domain.

Source entry ↗
49/50 residues mapped to 8WO1
Toll/interleukin-1 receptor homology (TIR) domainIPR000157672–839INTERPROdomain

This entry represents the Toll/interleukin-1 receptor (TIR) domain, which is the conserved cytoplasmic domain of approximately 200 amino acids, found in Toll-like receptors (TLRs) and their adaptors. Proteins containing this domain can also be found in plants, where they mediate disease resistance, and in bacteria, where they have been associated with virulence.

Full source description

This entry represents the Toll/interleukin-1 receptor (TIR) domain, which is the conserved cytoplasmic domain of approximately 200 amino acids, found in Toll-like receptors (TLRs) and their adaptors. Proteins containing this domain can also be found in plants, where they mediate disease resistance, and in bacteria, where they have been associated with virulence. Interestingly, the TIR domains from proteins present in all three major domains of life have been shown to cleave nicotinamide adenine dinucleotide (NAD+). In plants, TIR domains require self-association interfaces and a putative catalytic glutamic acid that is conserved in both bacterial TIR NAD+-cleaving enzymes (NADases) and the mammalian SARM1 (sterile alpha and TIR motif containing 1) NADase for cell death induction and NAD+ cleavage activity. It has been suggested that the primordial function of the TIR domain is the enzymatic cleavage of NAD+ and that the scaffolding function, which is best characterised in mammalian TIR domains involved in innate immunity, may be a more recent evolutionary adaptation. Toll proteins or Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R) superfamily are both involved in innate antibacterial and antifungal immunity in insects as well as in mammals. These receptors share a conserved cytoplasmic domain of approximately 200 amino acids, known as the Toll/IL-1R homologous region (TIR). The similarity between TLRs and IL-1Rs is not restricted to sequence homology since these proteins also share a similar signalling pathway. They both induce the activation of a Rel type transcription factor via an adaptor protein and a protein kinase. Interestingly, MyD88, a cytoplasmic adaptor protein found in mammals, contains a TIR domain associated to a DEATH domain. Besides the mammalian and Drosophila proteins, a TIR domain is also found in a number of plant cytoplasmic proteins implicated in host defense. Site directed mutagenesis and deletion analysis have shown that the TIR domain is essential for Toll and IL-1R activities. Sequence analysis have revealed the presence of three highly conserved regions among the different members of the family: box 1 (FDAFISY), box 2 (GYKLC-RD-PG), and box 3 (a conserved W surrounded by basic residues). It has been proposed that boxes 1 and 2 are involved in the binding of proteins involved in signalling, whereas box 3 is primarily involved in directing localization of receptor, perhaps through interactions with cytoskeletal element. Resolution of the crystal structures of the TIR domains of human Toll-like receptors 1 and 2 has shown that they contain a central five-stranded parallel β-sheet that is surrounded by a total of five helices on both sides, with connecting loop structures. The loop regions appear to play an important role in mediating the specificity of protein-protein interactions.

Source entry ↗
No verified residues in this structure

UniProt domains, repeats & motifs 20

Scroll across the table for evidence and actions.

20 recorded rows

FeaturePositionDescriptionEvidenceInspect
Repeat55–76LRR 1
Evidence & references

No separate evidence record is supplied for this statement.

22/22 residues mapped to 8WO1
Repeat79–100LRR 2
Evidence & references

No separate evidence record is supplied for this statement.

22/22 residues mapped to 8WO1
Repeat103–124LRR 3
Evidence & references

No separate evidence record is supplied for this statement.

22/22 residues mapped to 8WO1
Repeat127–148LRR 4
Evidence & references

No separate evidence record is supplied for this statement.

22/22 residues mapped to 8WO1
Repeat151–172LRR 5
Evidence & references

No separate evidence record is supplied for this statement.

22/22 residues mapped to 8WO1
Repeat176–199LRR 6
Evidence & references

No separate evidence record is supplied for this statement.

24/24 residues mapped to 8WO1
Repeat205–225LRR 7
Evidence & references

No separate evidence record is supplied for this statement.

21/21 residues mapped to 8WO1
Repeat227–247LRR 8
Evidence & references

No separate evidence record is supplied for this statement.

21/21 residues mapped to 8WO1
Repeat331–351LRR 9
Evidence & references

No separate evidence record is supplied for this statement.

21/21 residues mapped to 8WO1
Repeat352–373LRR 10
Evidence & references

No separate evidence record is supplied for this statement.

22/22 residues mapped to 8WO1
Repeat374–394LRR 11
Evidence & references

No separate evidence record is supplied for this statement.

21/21 residues mapped to 8WO1
Repeat400–422LRR 12
Evidence & references

No separate evidence record is supplied for this statement.

23/23 residues mapped to 8WO1
Repeat423–444LRR 13
Evidence & references

No separate evidence record is supplied for this statement.

22/22 residues mapped to 8WO1
Repeat448–456LRR 14
Evidence & references

No separate evidence record is supplied for this statement.

9/9 residues mapped to 8WO1
Repeat472–495LRR 15
Evidence & references

No separate evidence record is supplied for this statement.

24/24 residues mapped to 8WO1
Repeat497–518LRR 16
Evidence & references

No separate evidence record is supplied for this statement.

22/22 residues mapped to 8WO1
Repeat521–542LRR 17
Evidence & references

No separate evidence record is supplied for this statement.

22/22 residues mapped to 8WO1
Repeat545–565LRR 18
Evidence & references

No separate evidence record is supplied for this statement.

21/21 residues mapped to 8WO1
Domain579–629LRRCT
Evidence & references

No separate evidence record is supplied for this statement.

49/51 residues mapped to 8WO1
Domain672–815TIR
Sequence analysis
Evidence & references
  • ECO:0000255 PROSITE-ProRule:PRU00204
No verified residues in this structure

Functional sites 0

No annotation is recorded in this UniProt entry.

Sequence regions 0

No annotation is recorded in this UniProt entry.

10

Sequence & Isoforms

Sequence & isoforms

UniProt’s canonical sequence is its selected representative. It is not necessarily the dominant isoform in every tissue.

UniProt’s canonical sequence · O00206-1839 aa95,680 Da · source sequence mass

Full precursor sequence, including processing regions. The mass describes this unmodified source sequence, not every mature or modified product.

MMSASRLAGTLIPAMAFLSCVRPESWEPCVEVVPNITYQCMELNFYKIPDNLPFSTKNLDLSFNPLRHLGSYSFFSFPELQVLDLSRCEIQTIEDGAYQSLSHLSTLILTGNPIQSLALGAFSGLSSLQKLVAVETNLASLENFPIGHLKTLKELNVAHNLIQSFKLPEYFSNLTNLEHLDLSSNKIQSIYCTDLRVLHQMPLLNLSLDLSLNPMNFIQPGAFKEIRLHKLTLRNNFDSLNVMKTCIQGLAGLEVHRLVLGEFRNEGNLEKFDKSALEGLCNLTIEEFRLAYLDYYLDDIIDLFNCLTNVSSFSLVSVTIERVKDFSYNFGWQHLELVNCKFGQFPTLKLKSLKRLTFTSNKGGNAFSEVDLPSLEFLDLSRNGLSFKGCCSQSDFGTTSLKYLDLSFNGVITMSSNFLGLEQLEHLDFQHSNLKQMSEFSVFLSLRNLIYLDISHTHTRVAFNGIFNGLSSLEVLKMAGNSFQENFLPDIFTELRNLTFLDLSQCQLEQLSPTAFNSLSSLQVLNMSHNNFFSLDTFPYKCLNSLQVLDYSLNHIMTSKKQELQHFPSSLAFLNLTQNDFACTCEHQSFLQWIKDQRQLLVEVERMECATPSDKQGMPVLSLNITCQMNKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQLCLHYRDFIPGVAIAANIIHEGFHKSRKVIVVVSQHFIQSRWCIFEYEIAQTWQFLSSRAGIIFIVLQKVEKTLLRQQVELYRLLSRNTYLEWEDSVLGRHIFWRRLRKALLDGKSWNPEGTVGTGCNWQEATSI

Source isoform notes & selection

Alternative splicing

Complete source annotation
{
  "commentType": "ALTERNATIVE PRODUCTS",
  "events": [
    "Alternative splicing"
  ],
  "isoforms": [
    {
      "name": {
        "value": "1"
      },
      "isoformIds": [
        "O00206-1"
      ],
      "isoformSequenceStatus": "Displayed"
    },
    {
      "name": {
        "value": "2"
      },
      "isoformIds": [
        "O00206-2"
      ],
      "sequenceIds": [
        "VSP_035794"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "3"
      },
      "isoformIds": [
        "O00206-3"
      ],
      "sequenceIds": [
        "VSP_035793"
      ],
      "isoformSequenceStatus": "Described"
    }
  ]
}
  • O00206-1 · 1 · Displayed
    Complete source annotation
    {
      "name": {
        "value": "1"
      },
      "isoformIds": [
        "O00206-1"
      ],
      "isoformSequenceStatus": "Displayed"
    }
  • O00206-2 · 2 · Described · VSP_035794
    Complete source annotation
    {
      "name": {
        "value": "2"
      },
      "isoformIds": [
        "O00206-2"
      ],
      "sequenceIds": [
        "VSP_035794"
      ],
      "isoformSequenceStatus": "Described"
    }
  • O00206-3 · 3 · Described · VSP_035793
    Complete source annotation
    {
      "name": {
        "value": "3"
      },
      "isoformIds": [
        "O00206-3"
      ],
      "sequenceIds": [
        "VSP_035793"
      ],
      "isoformSequenceStatus": "Described"
    }

Isoform sequence differences 2

Scroll across the table for evidence and actions.

2 recorded rows

FeaturePositionDescriptionEvidenceInspect
Alternative sequenceVSP_0357931–200in isoform 3
Published statement 1 publication
Evidence & references
174/200 residues mapped to 8WO1
Alternative sequenceVSP_0357941–40in isoform 2
Published statement 2 publications
Evidence & references
14/40 residues mapped to 8WO1

Sequence conflicts & cautions 3

Scroll across the table for evidence and actions.

3 recorded rows

FeaturePositionDescriptionEvidenceInspect
Sequence conflict73in Ref. 11; ABU41664
S → R
Curator inference
Evidence & references
  • ECO:0000305
1/1 residues mapped to 8WO1
Sequence conflict400in Ref. 7; BAF82742
S → C
Curator inference
Evidence & references
  • ECO:0000305
1/1 residues mapped to 8WO1
Sequence conflict581in Ref. 7; BAG64706
F → S
Curator inference
Evidence & references
  • ECO:0000305
1/1 residues mapped to 8WO1

Recorded secondary structure 67

Scroll across the table for evidence and actions.

67 recorded rows

FeaturePositionDescriptionEvidenceInspect
Beta strand29–33Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z62
5/5 residues mapped to 8WO1
Turn34–36Turn
Evidence & references
  • ECO:0007829 PDB:2Z62
3/3 residues mapped to 8WO1
Beta strand37–39Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z62
3/3 residues mapped to 8WO1
Beta strand50–52Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z62
3/3 residues mapped to 8WO1
Beta strand58–60Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z62
3/3 residues mapped to 8WO1
Turn71–76Turn
Evidence & references
  • ECO:0007829 PDB:2Z62
6/6 residues mapped to 8WO1
Beta strand81–84Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z62
4/4 residues mapped to 8WO1
Beta strand91–93Beta strand
Evidence & references
  • ECO:0007829 PDB:8WO1
3/3 residues mapped to 8WO1
Turn95–100Turn
Evidence & references
  • ECO:0007829 PDB:2Z62
6/6 residues mapped to 8WO1
Beta strand106–108Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z62
3/3 residues mapped to 8WO1
Beta strand115–117Beta strand
Evidence & references
  • ECO:0007829 PDB:8WO1
3/3 residues mapped to 8WO1
Turn119–124Turn
Evidence & references
  • ECO:0007829 PDB:2Z62
6/6 residues mapped to 8WO1
Beta strand130–132Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z62
3/3 residues mapped to 8WO1
Beta strand141–145Beta strand
Evidence & references
  • ECO:0007829 PDB:8WO1
5/5 residues mapped to 8WO1
Beta strand154–156Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z62
3/3 residues mapped to 8WO1
Helix169–173Helix
Evidence & references
  • ECO:0007829 PDB:2Z62
5/5 residues mapped to 8WO1
Beta strand179–181Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z62
3/3 residues mapped to 8WO1
Helix192–195Helix
Evidence & references
  • ECO:0007829 PDB:2Z62
4/4 residues mapped to 8WO1
Helix196–199Helix
Evidence & references
  • ECO:0007829 PDB:2Z62
4/4 residues mapped to 8WO1
Beta strand206–209Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z62
4/4 residues mapped to 8WO1
Turn220–225Turn
Evidence & references
  • ECO:0007829 PDB:2Z63
6/6 residues mapped to 8WO1
Beta strand227–235Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z63
9/9 residues mapped to 8WO1
Helix242–248Helix
Evidence & references
  • ECO:0007829 PDB:2Z63
7/7 residues mapped to 8WO1
Turn249–252Turn
Evidence & references
  • ECO:0007829 PDB:2Z63
4/4 residues mapped to 8WO1
Beta strand254–262Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z63
9/9 residues mapped to 8WO1
Turn274–277Turn
Evidence & references
  • ECO:0007829 PDB:2Z63
4/4 residues mapped to 8WO1
Helix278–282Helix
Evidence & references
  • ECO:0007829 PDB:2Z63
5/5 residues mapped to 8WO1
Beta strand283–292Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z63
10/10 residues mapped to 8WO1
Beta strand295–298Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z63
4/4 residues mapped to 8WO1
Turn301–304Turn
Evidence & references
  • ECO:0007829 PDB:2Z63
4/4 residues mapped to 8WO1
Helix305–307Helix
Evidence & references
  • ECO:0007829 PDB:2Z63
3/3 residues mapped to 8WO1
Beta strand311–317Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z63
7/7 residues mapped to 8WO1
Beta strand319–322Beta strand
Evidence & references
  • ECO:0007829 PDB:4G8A
4/4 residues mapped to 8WO1
Helix324–327Helix
Evidence & references
  • ECO:0007829 PDB:4G8A
4/4 residues mapped to 8WO1
Beta strand333–339Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z63
7/7 residues mapped to 8WO1
Beta strand341–344Beta strand
Evidence & references
  • ECO:0007829 PDB:4G8A
4/4 residues mapped to 8WO1
Beta strand355–360Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z63
6/6 residues mapped to 8WO1
Beta strand377–379Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z63
3/3 residues mapped to 8WO1
Beta strand387–392Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
6/6 residues mapped to 8WO1
Helix393–396Helix
Evidence & references
  • ECO:0007829 PDB:2Z66
4/4 residues mapped to 8WO1
Beta strand403–405Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Beta strand410–419Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
10/10 residues mapped to 8WO1
Beta strand426–428Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Beta strand432–437Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
6/6 residues mapped to 8WO1
Turn438–445Turn
Evidence & references
  • ECO:0007829 PDB:2Z66
8/8 residues mapped to 8WO1
Beta strand451–453Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Turn464–469Turn
Evidence & references
  • ECO:0007829 PDB:2Z66
6/6 residues mapped to 8WO1
Beta strand475–477Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Helix484–486Helix
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Beta strand500–502Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Beta strand509–511Beta strand
Evidence & references
  • ECO:0007829 PDB:9J03
3/3 residues mapped to 8WO1
Turn513–518Turn
Evidence & references
  • ECO:0007829 PDB:2Z66
6/6 residues mapped to 8WO1
Beta strand524–526Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Helix538–540Helix
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Beta strand548–550Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Beta strand560–563Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
4/4 residues mapped to 8WO1
Beta strand573–575Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Helix585–587Helix
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Helix588–596Helix
Evidence & references
  • ECO:0007829 PDB:2Z66
9/9 residues mapped to 8WO1
Helix598–600Helix
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Helix604–606Helix
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Beta strand608–612Beta strand
Evidence & references
  • ECO:0007829 PDB:2Z66
5/5 residues mapped to 8WO1
Helix613–615Helix
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Beta strand617–619Beta strand
Evidence & references
  • ECO:0007829 PDB:8WTA
3/3 residues mapped to 8WO1
Helix620–622Helix
Evidence & references
  • ECO:0007829 PDB:2Z66
3/3 residues mapped to 8WO1
Beta strand627–629Beta strand
Evidence & references
  • ECO:0007829 PDB:5NAM
1/3 residues mapped to 8WO1
Helix630–662Helix
Evidence & references
  • ECO:0007829 PDB:5NAM
No verified residues in this structure
12

Homologs

OMA orthologs

Evolutionary relationships assigned by OMA, kept separate from sequence clusters. “1:1” describes an orthology relationship, not percentage identity.

Recorded preview of up to 12 orthologs; not an exhaustive list. Entries without a verified UniProt mapping open their OMA record.

13

Sources & References

Scientific descriptions and evidence come from the named sources. Atlas assembles the presentation and verifies residue mappings; it does not independently curate these claims.

Source dates & provenance

Recorded 2026-11-10. Source dates and identifiers are retained below.

Publications in this UniProt entry

1 · A human homologue of the Drosophila Toll protein signals activation of adaptive immunity.

1997 · Nature

PubMed 9237759 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); FUNCTION; SUBCELLULAR LOCATION; TISSUE SPECIFICITY

Medzhitov R., Preston-Hurlburt P., Janeway C.A. Jr.

2 · A family of human receptors structurally related to Drosophila Toll.

1998 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 9435236 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2); TISSUE SPECIFICITY

Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F.

3 · Phylogenetic variation and polymorphism at the Toll-like receptor 4 locus (TLR4).

2000 · Genome Biol.

PubMed 11104518 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [GENOMIC DNA]; FUNCTION; VARIANTS GLY-299 AND ILE-399; CHARACTERIZATION OF VARIANTS GLY-299 AND ILE-399; POLYMORPHISM

Smirnova I., Poltorak A., Chan E.K.L., McBride C., Beutler B.

4 · TLR4 mutations are associated with endotoxin hyporesponsiveness in humans.

2000 · Nat. Genet.

PubMed 10835634 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS GLY-299 AND ILE-399

Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., Frees K., Watt J.L., Schwartz D.A.

All source publications (52)
5 · Natural selection in the TLR-related genes in the course of primate evolution.

2008 · Immunogenetics

PubMed 18810425 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)

Nakajima T., Ohtani H., Satta Y., Uno Y., Akari H., Ishida T., Kimura A.

6 · The heterogeneous allelic repertoire of human Toll-Like receptor (TLR) genes.

2009 · PLoS ONE

PubMed 19924287 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS GLY-299 AND ILE-399

Georgel P., Macquin C., Bahram S.

7 · Complete sequencing and characterization of 21,243 full-length human cDNAs.

2004 · Nat. Genet.

PubMed 14702039 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3)

Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.

8 · DNA sequence and analysis of human chromosome 9.

2004 · Nature

PubMed 15164053 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]

Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., Dunham I.

· Reference

JUL-2005 ·

Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]

Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W., Venter J.C.

10 · The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).

2004 · Genome Res.

PubMed 15489334 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]

· Reference

MAR-2007 ·

Scope & authors

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-86

Liu Z., Li N., Wang J., Xiao W.

12 · Signal peptide prediction based on analysis of experimentally verified cleavage sites.

2004 · Protein Sci.

PubMed 15340161 ↗
Scope & authors

PROTEIN SEQUENCE OF 24-38

Zhang Z., Henzel W.J.

13 · Structural basis for signal transduction by the Toll/interleukin-1 receptor domains.

2000 · Nature

PubMed 11081518 ↗
Scope & authors

MUTAGENESIS OF GLU-697; ARG-710; ASP-711 AND PRO-714

Xu Y., Tao X., Shen B., Horng T., Medzhitov R., Manley J.L., Tong L.

14 · Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2.

2001 · J. Biol. Chem.

PubMed 11274165 ↗
Scope & authors

SUBUNIT; SUBCELLULAR LOCATION

da Silva Correia J., Soldau K., Christen U., Tobias P.S., Ulevitch R.J.

15 · MD-2 and TLR4 N-linked glycosylations are important for a functional lipopolysaccharide receptor.

2002 · J. Biol. Chem.

PubMed 11706042 ↗
Scope & authors

GLYCOSYLATION AT ASN-35; ASN-173; ASN-205; ASN-282; ASN-309; ASN-497; ASN-526; ASN-575 AND ASN-624; MUTAGENESIS OF ASN-526 AND ASN-575

da Silva Correia J., Ulevitch R.J.

16 · TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferon-beta.

2003 · J. Biol. Chem.

PubMed 14519765 ↗
Scope & authors

INTERACTION WITH TICAM2

Oshiumi H., Sasai M., Shida K., Fujita T., Matsumoto M., Seya T.

17 · LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF.

2003 · J. Exp. Med.

PubMed 14517278 ↗
Scope & authors

FUNCTION

Fitzgerald K.A., Rowe D.C., Barnes B.J., Caffrey D.R., Visintin A., Latz E., Monks B., Pitha P.M., Golenbock D.T.

18 · Regulation of IFN regulatory factor-7 and IFN-alpha production by enveloped virus and lipopolysaccharide in human plasmacytoid dendritic cells.

2004 · J. Immunol.

PubMed 15265881 ↗
Scope & authors

FUNCTION; INDUCTION BY LPS

Dai J., Megjugorac N.J., Amrute S.B., Fitzgerald-Bocarsly P.

19 · Direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B.

2004 · J. Immunol.

PubMed 15356101 ↗
Scope & authors

INTERACTION WITH NOX4

Park H.S., Jung H.Y., Park E.Y., Kim J., Lee W.J., Bae Y.S.

20 · Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals.

2005 · J. Biol. Chem.

PubMed 15809303 ↗
Scope & authors

FUNCTION

Bulut Y., Michelsen K.S., Hayrapetian L., Naiki Y., Spallek R., Singh M., Arditi M.

21 · Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.

2005 · Nat. Immunol.

PubMed 15852007 ↗
Scope & authors

FUNCTION; INTERACTION WITH CD180

Divanovic S., Trompette A., Atabani S.F., Madan R., Golenbock D.T., Visintin A., Finberg R.W., Tarakhovsky A., Vogel S.N., Belkaid Y., Kurt-Jones E.A., Karp C.L.

22 · The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-activated protein kinase pathway and release of proinflammatory cytokines through Toll-like receptors 2 and 4 in human monocytes.

2006 · Infect. Immun.

PubMed 16622205 ↗
Scope & authors

FUNCTION

Jung S.B., Yang C.S., Lee J.S., Shin A.R., Jung S.S., Son J.W., Harding C.V., Kim H.J., Park J.K., Paik T.H., Song C.H., Jo E.K.

23 · Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway.

2007 · Virology

PubMed 17292937 ↗
Scope & authors

FUNCTION

Georgel P., Jiang Z., Kunz S., Janssen E., Mols J., Hoebe K., Bahram S., Oldstone M.B., Beutler B.

24 · Effects of TREM-1 activation in human neutrophils: activation of signaling pathways, recruitment into lipid rafts and association with TLR4.

2007 · Int. Immunol.

PubMed 17098818 ↗
Scope & authors

INTERACTION WITH TREM1; SUBCELLULAR LOCATION

Fortin C.F., Lesur O., Fulop T. Jr.

25 · Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity.

2007 · Circ. Res.

PubMed 17478729 ↗
Scope & authors

FUNCTION

Kim F., Pham M., Luttrell I., Bannerman D.D., Tupper J., Thaler J., Hawn T.R., Raines E.W., Schwartz M.W.

26 · Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a substrate-specific cochaperone.

2010 · Nat. Commun.

PubMed 20865800 ↗
Scope & authors

INTERACTION WITH HSP90B1

Liu B., Yang Y., Qiu Z., Staron M., Hong F., Li Y., Wu S., Li Y., Hao B., Bona R., Han D., Li Z.

27 · TREM-1 interaction with the LPS/TLR4 receptor complex.

2011 · Eur. Cytokine Netw.

PubMed 21393102 ↗
Scope & authors

FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH TREM1

Arts R.J., Joosten L.A., Dinarello C.A., Kullberg B.J., van der Meer J.W., Netea M.G.

· Reference

2012 · Nat. Commun.

Scope & authors

ERRATUM OF PUBMED:20865800

Liu B., Yang Y., Qiu Z., Staron M., Hong F., Li Y., Wu S., Li Y., Hao B., Bona R., Han D., Li Z.

29 · CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer.

2010 · Nat. Immunol.

PubMed 20037584 ↗
Scope & authors

FUNCTION; INTERACTION WITH CD36 AND TLR6; SUBCELLULAR LOCATION

Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A., Lacy-Hulbert A., El Khoury J., Golenbock D.T., Moore K.J.

30 · Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1.

2010 · J. Virol.

PubMed 19846529 ↗
Scope & authors

FUNCTION; INTERACTION WITH EBOLA VIRUS GLYCOPROTEIN (MICROBIAL INFECTION)

Okumura A., Pitha P.M., Yoshimura A., Harty R.N.

31 · Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel.

2010 · Nat. Immunol.

PubMed 20711192 ↗
Scope & authors

FUNCTION; MUTAGENESIS OF HIS-431; HIS-456 AND HIS-458; INVOLVEMENT IN CONTACT ALLERGY TO NICKEL

Schmidt M., Raghavan B., Mueller V., Vogl T., Fejer G., Tchaptchet S., Keck S., Kalis C., Nielsen P.J., Galanos C., Roth J., Skerra A., Martin S.F., Freudenberg M.A., Goebeler M.

32 · MLK4 has negative effect on TLR4 signaling.

2012 · Cell. Mol. Immunol.

PubMed 21602844 ↗
Scope & authors

INTERACTION WITH MAP3K21

Seit-Nebi A., Cheng W., Xu H., Han J.

33 · CD14 and TLR4 mediate cytokine release promoted by electronegative LDL in monocytes.

2013 · Atherosclerosis

PubMed 23880187 ↗
Scope & authors

FUNCTION

Estruch M., Bancells C., Beloki L., Sanchez-Quesada J.L., Ordonez-Llanos J., Benitez S.

34 · Molecular mechanisms for the subversion of MyD88 signaling by TcpC from virulent uropathogenic Escherichia coli.

2013 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 23569230 ↗
Scope & authors

INTERACTION WITH E.COLI PROTEIN TCPC (MICROBIAL INFECTION)

Snyder G.A., Cirl C., Jiang J., Chen K., Waldhuber A., Smith P., Roemmler F., Snyder N., Fresquez T., Duerr S., Tjandra N., Miethke T., Xiao T.S.

35 · Mechanism of bacterial interference with TLR4 signaling by Brucella Toll/interleukin-1 receptor domain-containing protein TcpB.

2014 · J. Biol. Chem.

PubMed 24265315 ↗
Scope & authors

INTERACTION WITH B.MELITENSIS PROTEIN TCPB (MICROBIAL INFECTION)

Alaidarous M., Ve T., Casey L.W., Valkov E., Ericsson D.J., Ullah M.O., Schembri M.A., Mansell A., Sweet M.J., Kobe B.

36 · WDFY1 mediates TLR3/4 signaling by recruiting TRIF.

2015 · EMBO Rep.

PubMed 25736436 ↗
Scope & authors

INTERACTION WITH TICAM1 AND TICAM2

Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B., Liu Y.

37 · Raftlin controls lipopolysaccharide-induced TLR4 internalization and TICAM-1 signaling in a cell type-specific manner.

2016 · J. Immunol.

PubMed 27022195 ↗
Scope & authors

FUNCTION; INTERACTION WITH RFTN1; SUBCELLULAR LOCATION; TISSUE SPECIFICITY; INDUCTION BY LPS

Tatematsu M., Yoshida R., Morioka Y., Ishii N., Funami K., Watanabe A., Saeki K., Seya T., Matsumoto M.

38 · NMI and IFP35 serve as proinflammatory DAMPs during cellular infection and injury.

2017 · Nat. Commun.

PubMed 29038465 ↗
Scope & authors

FUNCTION

Xiahou Z., Wang X., Shen J., Zhu X., Xu F., Hu R., Guo D., Li H., Tian Y., Liu Y., Liang H.

39 · The SARM1 Toll/Interleukin-1 receptor domain possesses intrinsic NAD+ cleavage activity that promotes pathological axonal degeneration.

2017 · Neuron

PubMed 28334607 ↗
Scope & authors

LACK OF NADASE ACTIVITY

Essuman K., Summers D.W., Sasaki Y., Mao X., DiAntonio A., Milbrandt J.

40 · TRAF3-interacting JNK-activating modulator promotes inflammation by stimulating translocation of Toll-like receptor 4 to lipid rafts.

2019 · J. Biol. Chem.

PubMed 30573680 ↗
Scope & authors

INTERACTION WITH TRAF3IP3

Li Y., Guan J., Wang W., Hou C., Zhou L., Ma J., Cheng Y., Jiao S., Zhou Z.

41 · Mycoplasma pneumoniae lipids license TLR-4 for activation of NLRP3 inflammasome and autophagy to evoke a proinflammatory response.

2021 · Clin. Exp. Immunol.

PubMed 32894580 ↗
Scope & authors

FUNCTION

Luo H., He J., Qin L., Chen Y., Chen L., Li R., Zeng Y., Zhu C., You X., Wu Y.

42 · PAUF Induces Migration of Human Pancreatic Cancer Cells Exclusively via the TLR4/MyD88/NF-kappaB Signaling Pathway.

2022 · Int. J. Mol. Sci.

PubMed 36232715 ↗
Scope & authors

FUNCTION; SUBCELLULAR LOCATION; TISSUE SPECIFICITY; INTERACTION WITH ZG16B/PAUF; TICAM1 AND MYD88

Youn S.E., Jiang F., Won H.Y., Hong D.E., Kang T.H., Park Y.Y., Koh S.S.

43 · Recombinant human KAI1/CD82 attenuates M1 macrophage polarization on LPS-stimulated RAW264.7 cells via blocking TLR4/JNK/NF-kappaB signal pathway.

2023 · BMB Rep.

PubMed 36945827 ↗
Scope & authors

FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH CD82

Lee H., Han J.H., An K., Kang Y.J., Hwangbo H., Heo J.H., Choi B.H., Kim J.J., Kim S.R., Lee S.Y., Hur J.

44 · RNF128 regulates neutrophil infiltration and myeloperoxidase functions to prevent acute lung injury.

2023 · Cell Death Dis.

PubMed 37344492 ↗
Scope & authors

FUNCTION; UBIQUITINATION BY RNF128

Liu P.Y., Chen C.Y., Lin Y.L., Lin C.M., Tsai W.C., Tsai Y.L., Lin G.J., Chen Y.G., Wang S.Y., Sun R.N., Huang Y.C., Chang H., Chen Y.C.

45 · A mosquito salivary protein-driven influx of myeloid cells facilitates flavivirus transmission.

2024 · EMBO J.

PubMed 38378891 ↗
Scope & authors

INTERACTION WITH MOSQUITO NEUTROPHIL RECRUITMENT PROTEIN

Wang Z., Nie K., Liang Y., Niu J., Yu X., Zhang O., Liu L., Shi X., Wang Y., Feng X., Zhu Y., Wang P., Cheng G.

46 · Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-kappaB.

2024 · Cell

PubMed 38670073 ↗
Scope & authors

SUBCELLULAR LOCATION; GLYCOSYLATION AT ASN-526 AND ASN-575

Lampson B.L., Ramrez A.S., Baro M., He L., Hegde M., Koduri V., Pfaff J.L., Hanna R.E., Kowal J., Shirole N.H., He Y., Doench J.G., Contessa J.N., Locher K.P., Kaelin W.G.

47 · Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran.

2007 · Cell

PubMed 17803912 ↗
Scope & authors

X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH LY96; SUBUNIT; DISULFIDE BONDS; GLYCOSYLATION AT ASN-35; ASN-173 AND ASN-205

Kim H.M., Park B.S., Kim J.-I., Kim S.E., Lee J., Oh S.C., Enkhbayar P., Matsushima N., Lee H., Yoo O.J., Lee J.-O.

48 · The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex.

2009 · Nature

PubMed 19252480 ↗
Scope & authors

X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH LY96 AND LIPOPOLYSACCHARIDE; SUBUNIT; DISULFIDE BONDS; GLYCOSYLATION AT ASN-173; ASN-205; ASN-497 AND ASN-526 AND ASN-575

Park B.S., Song D.H., Kim H.M., Choi B.-S., Lee H., Lee J.-O.

49 · Structure-based rational design of a Toll-like receptor 4 (TLR4) decoy receptor with high binding affinity for a target protein.

2012 · PLoS ONE

PubMed 22363519 ↗
Scope & authors

X-RAY CRYSTALLOGRAPHY; GLYCOSYLATION AT ASN-35 AND ASN-173; DISULFIDE BONDS

Han J., Kim H.J., Lee S.C., Hong S., Park K., Jeon Y.H., Kim D., Cheong H.K., Kim H.S.

50 · Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans.

2001 · Genetics

PubMed 11514453 ↗
Scope & authors

VARIANTS ARG-188; SER-246; GLY-299; SER-329; ILE-399; LEU-443; LYS-474; HIS-510; ARG-694; HIS-763 AND HIS-834

Smirnova I., Hamblin M.T., McBride C., Beutler B., Di Rienzo A.

51 · Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration.

2005 · Hum. Mol. Genet.

PubMed 15829498 ↗
Scope & authors

VARIANT GLY-299; ASSOCIATION WITH ARMD SUSCEPTIBILITY

Zareparsi S., Buraczynska M., Branham K.E.H., Shah S., Eng D., Li M., Pawar H., Yashar B.M., Moroi S.E., Lichter P.R., Petty H.R., Richards J.E., Abecasis G.R., Elner V.M., Swaroop A.

52 · Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in insulin-producing adenomas.

2015 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 25787250 ↗
Scope & authors

VARIANT ASP-287

Cromer M.K., Choi M., Nelson-Williams C., Fonseca A.L., Kunstman J.W., Korah R.M., Overton J.D., Mane S., Kenney B., Malchoff C.D., Stalberg P., Akerstroem G., Westin G., Hellman P., Carling T., Bjoerklund P., Lifton R.P.

Protein Spotlight ↗

Annotation coverage audit

Every recorded UniProt comment and feature has a destination in this page. GO, Atlas annotations and interaction rows retain their separate source counts.

158 source comments and features accounted for.

View annotation inventory
Source recordTypeSection
FUNCTION:0FUNCTIONfunction
SUBUNIT:0SUBUNITinteractions
SUBUNIT:1SUBUNITinteractions
SUBUNIT:2SUBUNITinteractions
SUBUNIT:3SUBUNITinteractions
INTERACTION:0INTERACTIONinteractions
SUBCELLULAR LOCATION:0SUBCELLULAR LOCATIONlocation
ALTERNATIVE PRODUCTS:0ALTERNATIVE PRODUCTSsequence
TISSUE SPECIFICITY:0TISSUE SPECIFICITYexpression
INDUCTION:0INDUCTIONexpression
DOMAIN:0DOMAINdomains
PTM:0PTMprocessing
PTM:1PTMprocessing
PTM:2PTMprocessing
POLYMORPHISM:0POLYMORPHISMdisease
MISCELLANEOUS:0MISCELLANEOUSfunction
SIMILARITY:0SIMILARITYdomains
CAUTION:0CAUTIONfunction
WEB RESOURCE:0WEB RESOURCEsources
feature-0Signalprocessing
feature-1Chainprocessing
feature-2Topological domainlocation
feature-3Transmembranelocation
feature-4Topological domainlocation
feature-5Repeatdomains
feature-6Repeatdomains
feature-7Repeatdomains
feature-8Repeatdomains
feature-9Repeatdomains
feature-10Repeatdomains
feature-11Repeatdomains
feature-12Repeatdomains
feature-13Repeatdomains
feature-14Repeatdomains
feature-15Repeatdomains
feature-16Repeatdomains
feature-17Repeatdomains
feature-18Repeatdomains
feature-19Repeatdomains
feature-20Repeatdomains
feature-21Repeatdomains
feature-22Repeatdomains
feature-23Domaindomains
feature-24Domaindomains
feature-25Glycosylationprocessing
feature-26Glycosylationprocessing
feature-27Glycosylationprocessing
feature-28Glycosylationprocessing
feature-29Glycosylationprocessing
feature-30Glycosylationprocessing
feature-31Glycosylationprocessing
feature-32Glycosylationprocessing
feature-33Glycosylationprocessing
feature-34Glycosylationprocessing
feature-35Disulfide bondprocessing
feature-36Disulfide bondprocessing
feature-37Disulfide bondprocessing
feature-38Disulfide bondprocessing
feature-39Disulfide bondprocessing
feature-40Alternative sequencesequence
feature-41Alternative sequencesequence
feature-42Natural variantdisease
feature-43Natural variantdisease
feature-44Natural variantdisease
feature-45Natural variantdisease
feature-46Natural variantdisease
feature-47Natural variantdisease
feature-48Natural variantdisease
feature-49Natural variantdisease
feature-50Natural variantdisease
feature-51Natural variantdisease
feature-52Natural variantdisease
feature-53Natural variantdisease
feature-54Natural variantdisease
feature-55Natural variantdisease
feature-56Natural variantdisease
feature-57Natural variantdisease
feature-58Natural variantdisease
feature-59Natural variantdisease
feature-60Mutagenesisdisease
feature-61Mutagenesisdisease
feature-62Mutagenesisdisease
feature-63Mutagenesisdisease
feature-64Mutagenesisdisease
feature-65Mutagenesisdisease
feature-66Mutagenesisdisease
feature-67Mutagenesisdisease
feature-68Mutagenesisdisease
feature-69Sequence conflictsequence
feature-70Sequence conflictsequence
feature-71Sequence conflictsequence
feature-72Beta strandsequence
feature-73Turnsequence
feature-74Beta strandsequence
feature-75Beta strandsequence
feature-76Beta strandsequence
feature-77Turnsequence
feature-78Beta strandsequence
feature-79Beta strandsequence
feature-80Turnsequence
feature-81Beta strandsequence
feature-82Beta strandsequence
feature-83Turnsequence
feature-84Beta strandsequence
feature-85Beta strandsequence
feature-86Beta strandsequence
feature-87Helixsequence
feature-88Beta strandsequence
feature-89Helixsequence
feature-90Helixsequence
feature-91Beta strandsequence
feature-92Turnsequence
feature-93Beta strandsequence
feature-94Helixsequence
feature-95Turnsequence
feature-96Beta strandsequence
feature-97Turnsequence
feature-98Helixsequence
feature-99Beta strandsequence
feature-100Beta strandsequence
feature-101Turnsequence
feature-102Helixsequence
feature-103Beta strandsequence
feature-104Beta strandsequence
feature-105Helixsequence
feature-106Beta strandsequence
feature-107Beta strandsequence
feature-108Beta strandsequence
feature-109Beta strandsequence
feature-110Beta strandsequence
feature-111Helixsequence
feature-112Beta strandsequence
feature-113Beta strandsequence
feature-114Beta strandsequence
feature-115Beta strandsequence
feature-116Turnsequence
feature-117Beta strandsequence
feature-118Turnsequence
feature-119Beta strandsequence
feature-120Helixsequence
feature-121Beta strandsequence
feature-122Beta strandsequence
feature-123Turnsequence
feature-124Beta strandsequence
feature-125Helixsequence
feature-126Beta strandsequence
feature-127Beta strandsequence
feature-128Beta strandsequence
feature-129Helixsequence
feature-130Helixsequence
feature-131Helixsequence
feature-132Helixsequence
feature-133Beta strandsequence
feature-134Helixsequence
feature-135Beta strandsequence
feature-136Helixsequence
feature-137Beta strandsequence
feature-138Helixsequence